<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/2021.03.30.437774</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;2021.03.30.437774</article-id><article-id pub-id-type="other" hwp:sub-type="slug">2021.03.30.437774</article-id><article-id pub-id-type="other" hwp:sub-type="atom-slug">2021.03.30.437774</article-id><article-id pub-id-type="other" hwp:sub-type="tag">2021.03.30.437774</article-id><article-version>1.3</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Cancer Biology" hwp:journal="biorxiv"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">The long non-coding RNA <italic toggle="yes">MaTAR20</italic> promotes mammary tumor growth by regulating angiogenesis pathways</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1 xref-corresp-1-2"><label>*</label>Correspondence: Sarah D. Diermeier (<email hwp:id="email-1">sarah.diermeier@otago.ac.nz</email>, +64 20 4221985) or David L. Spector (<email hwp:id="email-2">spector@cshl.edu</email>, +1 (516) 367-8456)</corresp><fn id="n1" fn-type="supported-by" hwp:id="fn-1"><p hwp:id="p-1"><bold>Financial Support:</bold> This research was supported by NCI 5P01CA013106-Project 3 (D.L.S.), CSHL/Northwell Health support (D.L.S), a Susan G. Komen postdoctoral fellowship (S.D.D.), NCI 1K99CA215362-01 (S.D.D), RDF-UOO1802 awarded by the Royal Society Te Apārangi (S.D.D.), the New Zealand Cancer Society (S.D.D.) and the Breast Cancer Foundation New Zealand (S.D.D.).</p></fn><fn id="n2" fn-type="conflict" hwp:id="fn-2"><p hwp:id="p-2"><bold>Conflict of interest:</bold> The authors declare no conflict of interest. D.L.S. is a consultant to, and receives research reagents from, Ionis Pharmaceuticals.</p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6120-2744</contrib-id><name name-style="western" hwp:sortable="Diermeier Sarah D."><surname>Diermeier</surname><given-names>Sarah D.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-6120-2744"/></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Chang Kung-Chi"><surname>Chang</surname><given-names>Kung-Chi</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Frewen Ashleigh"><surname>Frewen</surname><given-names>Ashleigh</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Taaffe Padraig"><surname>Taaffe</surname><given-names>Padraig</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Grans Joke C."><surname>Grans</surname><given-names>Joke C.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Xiong Haoyu"><surname>Xiong</surname><given-names>Haoyu</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Benz Brian A."><surname>Benz</surname><given-names>Brian A.</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-3" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Russo Suzanne"><surname>Russo</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-4" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Nowak Dawid"><surname>Nowak</surname><given-names>Dawid</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-5" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Hearn Stephen"><surname>Hearn</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-6" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-11"><name name-style="western" hwp:sortable="Yu Allen"><surname>Yu</surname><given-names>Allen</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-7" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-12"><name name-style="western" hwp:sortable="Wilkinson John E."><surname>Wilkinson</surname><given-names>John E.</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-13"><name name-style="western" hwp:sortable="Rigo Frank"><surname>Rigo</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-14"><name name-style="western" hwp:sortable="Spector David L."><surname>Spector</surname><given-names>David L.</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-8" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-2" hwp:rel-id="aff-3">3</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-2" hwp:rel-id="corresp-1">*</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5"><label>1</label><institution hwp:id="institution-1">Department of Biochemistry, University of Otago</institution>, Dunedin 9016, <country>New Zealand</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2 xref-aff-2-3 xref-aff-2-4 xref-aff-2-5 xref-aff-2-6 xref-aff-2-7 xref-aff-2-8"><label>2</label><institution hwp:id="institution-2">Cold Spring Harbor Laboratory</institution>, Cold Spring Harbor, NY 11724, <country>USA</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1 xref-aff-3-2"><label>3</label><institution hwp:id="institution-3">Stony Brook University, Molecular and Cellular Biology Program</institution>, Stony Brook, NY 11794, <country>USA</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2"><label>4</label><institution hwp:id="institution-4">Stony Brook University, Genetics Program</institution>, Stony Brook, NY 11794, <country>USA</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-5">Department of Pathology, University of Michigan</institution>, Ann Arbor, MI 48109, <country>USA</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">Ionis Pharmaceuticals</institution>, Carlsbad, CA 92010, <country>USA</country></aff></contrib-group><pub-date pub-type="epub-original" date-type="pub" publication-format="electronic" hwp:start="2021"><year>2021</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2021-03-31T13:36:13-07:00">
    <day>31</day><month>3</month><year>2021</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2021-10-26T03:33:21-07:00">
    <day>26</day><month>10</month><year>2021</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2021-03-31T13:39:50-07:00">
    <day>31</day><month>3</month><year>2021</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2021-10-26T03:41:27-07:00">
    <day>26</day><month>10</month><year>2021</year>
  </pub-date><elocation-id>2021.03.30.437774</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2021-03-30"><day>30</day><month>3</month><year>2021</year></date>
<date date-type="rev-recd" hwp:start="2021-10-26"><day>26</day><month>10</month><year>2021</year></date>
<date date-type="accepted" hwp:start="2021-10-26"><day>26</day><month>10</month><year>2021</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2021</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-3">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="437774.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/change-list" xlink:role="change-list" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2021/pdf/2021.03.30.437774v3.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="437774.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2021/abstracts/2021.03.30.437774v3/2021.03.30.437774v3.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2021/fulltext/2021.03.30.437774v3/2021.03.30.437774v3.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-4">Long non-coding RNAs (lncRNAs) are an emerging class of regulatory molecules that have been shown to play important roles in tumorigenesis and cancer progression. Here, we studied the recently identified lncRNA <italic toggle="yes">Mammary Tumor Associated RNA 20</italic> (<italic toggle="yes">MaTAR20</italic>) in mammary cancer progression. A CRISPR/Cas9 knockout of <italic toggle="yes">MaTAR20</italic> in the metastatic 4T1 cell line led to reduced cancer cell proliferation and increased cell surface adhesion compared to control cells. Consistent with these knockout results antisense oligonucleotide (ASO) mediated knockdown of <italic toggle="yes">MaTAR20</italic> resulted in reduced growth and invasion in 4T1 cells, and in primary mammary tumor organoids derived from the MMTV-PyMT mouse model of breast cancer. Injection of <italic toggle="yes">MaTAR20</italic>-specific ASOs subcutaneously into tumor bearing MMTV-PyMT mice resulted in smaller and highly necrotic tumors in comparison to mice injected with a scrambled control ASO. To investigate the molecular mechanism by which <italic toggle="yes">MaTAR20</italic> acts to advance mammary tumor progression, we applied a combination of RNA-sequencing and RNA-pulldown coupled to DNA-sequencing. These analyses demonstrated that the nuclear retained lncRNA is associated with several essential cancer signaling pathways such as VEGF signaling. In particular, <italic toggle="yes">MaTAR20</italic> directly binds to and regulates the expression of <italic toggle="yes">Tnfsf15</italic>. Our results indicate that <italic toggle="yes">MaTAR20</italic> is an important driver of mammary tumor progression and represents a promising new therapeutic target.</p></abstract><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-2">Keywords</title><kwd hwp:id="kwd-1">long non-coding RNAs</kwd><kwd hwp:id="kwd-2">breast cancer</kwd><kwd hwp:id="kwd-3">antisense oligonucleotides</kwd><kwd hwp:id="kwd-4">Vegf</kwd><kwd hwp:id="kwd-5">Tnfsf15</kwd></kwd-group><counts><page-count count="69"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta><notes hwp:id="notes-1"><notes notes-type="competing-interest-statement" hwp:id="notes-2"><title hwp:id="title-3">Competing Interest Statement</title><p hwp:id="p-5">The authors declare no conflict of interest. D.L.S. is a consultant to, and receives research reagents from, Ionis Pharmaceuticals.</p></notes><fn-group content-type="summary-of-updates" hwp:id="fn-group-1"><title hwp:id="title-4">Summary of Updates:</title><fn fn-type="update" hwp:id="fn-3"><p hwp:id="p-6">Human data - Figures 3 and S4</p></fn></fn-group></notes></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-5">Introduction</title><p hwp:id="p-7">Breast cancer (BC) is estimated to account for 30% of new cancer diagnoses and 15% of cancer-related deaths in women in 2021 (<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>). While currently available chemo- and targeted therapies have led to improved overall survival rates, declines of mortality have slowed over the past decade compared to other types of cancer (<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-2" hwp:rel-id="ref-1">1</xref>). Metastatic disease in particular is the main cause for BC related mortality (<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-3" hwp:rel-id="ref-1">1</xref>), indicating the need for innovative approaches to target the metastatic cascade.</p><p hwp:id="p-8">Recent studies highlight the potential of long non-coding RNAs (lncRNAs) as new therapeutic targets in cancer (<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>–<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>). Many lncRNAs are expressed in a tissue- and cancer-specific manner (<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>, <xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>) and several previous studies have supported a role for lncRNAs as drivers of tumorigenesis, tumor growth and invasion (reviewed in (<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>) and (<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>)). A promising new approach of targeting lncRNAs to reduce mammary tumor growth and metastasis <italic toggle="yes">in vivo</italic> are nucleic acid based therapies (reviewed in (<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-2" hwp:rel-id="ref-17">17</xref>)). Initial success in targeting oncogenic lncRNAs was shown using locked nucleic acids (LNAs) to target <italic toggle="yes">BCAR4</italic> (<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>) or antisense oligonucleotides (ASOs) for <italic toggle="yes">Malat1</italic> (<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>, <xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>).</p><p hwp:id="p-9">We previously identified 30 <italic toggle="yes"><underline>Ma</underline>mmary <underline>T</underline>umor <underline>A</underline>ssociated <underline>R</underline>NAs</italic> (<italic toggle="yes">MaTARs</italic>) (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>). These lncRNAs are over-expressed in mouse models of BC and in human breast tumor tissue compared to normal mammary epithelial cells (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-2" hwp:rel-id="ref-7">7</xref>). ASO-mediated knockdown of various <italic toggle="yes">MaTARs</italic> in primary mammary tumor cells resulted in a tumor cell - specific reduction of cell growth (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-3" hwp:rel-id="ref-7">7</xref>). Recently, we demonstrated that <italic toggle="yes">MaTAR25</italic> expression contributes to BC progression via regulation of the <italic toggle="yes">Tensin1</italic> gene (<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref>). Here, we investigated the potential of <italic toggle="yes">MaTAR20</italic> (also known as <italic toggle="yes">Gm13387</italic>, <italic toggle="yes">RP23-132N23.1</italic>, <italic toggle="yes">ENSMUSG00000087028</italic>) as a new therapeutic target in BC, as well as the molecular mechanism by which <italic toggle="yes">MaTAR20</italic> acts. ASO-mediated knockdown or CRISPR/Cas9 knockout of <italic toggle="yes">MaTAR20</italic> results in reduced cell proliferation and migration. Further, ASO knockdown of <italic toggle="yes">MaTAR20 in vivo</italic> leads to delayed tumor onset, decreased tumor size, increased tumor necrosis and reduced metastatic burden. To further study the potential of this lncRNAs as a therapeutic target, we generated two loss-of-function and one gain- of-function models of the human orthologue, <italic toggle="yes">hMaTAR20</italic>. Our <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> characterization of these models suggest that the lncRNA is indeed a new driver of breast cancer cell proliferation and migration. Based on our investigation of the molecular mechanism of <italic toggle="yes">MaTAR20</italic> function, the observed phenotype is likely the result of reduced tumor vascularization upon reduction in the level of <italic toggle="yes">MaTAR20</italic>. <italic toggle="yes">MaTAR20</italic> regulates genes involved in tumor angiogenesis, such as increasing the expression of the <italic toggle="yes">Vascular Endothelial Growth Factor A and B</italic> (<italic toggle="yes">Vegf-A</italic>, <italic toggle="yes">Vegf-B</italic>) genes and it directly binds to the <italic toggle="yes">Tnfsf15</italic> locus to repress its expression during tumor progression.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-6">Materials and Methods</title><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-7">Murine cell culture</title><p hwp:id="p-10">Murine 4T1, Py2T, G0771 and D2A cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were grown in a cell culture incubator at 37 °C and 5% CO2. ASOs were delivered to the cells via free uptake immediately after seeding the cells. For proliferation assays, cells were seeded in 24-well plates and trypsinized at individual time points. Cell counts were determined manually using a hemocytometer. Cell cycle analysis was performed using a BrdU FITC kit (BD) as described (<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-3" hwp:rel-id="ref-13">13</xref>).</p></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-8">Organoid culture</title><p hwp:id="p-11">Murine mammary tumor organoids were generated and cultured as previously described (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-4" hwp:rel-id="ref-7">7</xref>, <xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>). Briefly, organoids were generated from nulliparous MMTV-PyMT tumors, mixed with growth factor-reduced Matrigel and grown in DMEM/F12 medium supplemented with 1x ITS (insulin, transferrin, and sodium selenite), 1% penicillin/streptomycin and murine FGF2 (2.5 nM). For ASO-mediated knockdown experiments, organoids were seeded at a density of 5 organoids/µl and plated as 80 µl domes in 24-well dishes. ASOs were added directly (free uptake) to the culture medium 15-20 min after the organoids were plated and in fresh medium at day 3. Organoids were incubated for a total of 6 days. ASO sequences are provided in Supplementary Table S1. For visualization purposes and quantification of organoid branching, images were acquired using an Axio-Observer Live Cell inverted microscope (Zeiss).</p></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-9">Scanning electron microscopy (SEM)</title><p hwp:id="p-12">SEM on 2D cells was performed as described previously (<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>). Briefly, cells cultured on glass coverslips were fixed in 1.6% glutaraldehyde in PBS for 30 minutes and then dehydrated in a graded ethanol series. Coverslips were critical point dried (CPD) using a Samidri 795 CPD device (Tousimis), mounted on aluminum stubs with carbon tabs (Electron Microscopy Sciences). Samples were coated with gold using an Emitech K550X Sputter Coater. Samples were imaged with a Hitachi S3500 SEM operated at 5 kV.</p><p hwp:id="p-13">For SEM of 3D organoids, Matrigel containing organoid samples were removed from multi-well tissue culture dishes (using a 3.5 mL disposable transfer pipette and placed in 45 mL of cold PBS (4°C) in 50 mL capacity polypropylene centrifuge tubes (VWR Scientific). Matrigel was washed away by 3-4 rounds of suspension in cold PBS and centrifugation using a refrigerated centrifuge set to 1,000 pm, 20 min, 4°C (Beckman Coulter Allegra X15r). After the final wash to remove Matrigel, organoids were transferred to 1.6 mL microcentrifuge tubes and fixed in 1% glutaraldehyde in PBS at 4°C, for 30 minutes, rinsed in distilled water by centrifugation and resuspension and then post-fixed in 1% aqueous osmium tetroxide (Electron Microscopy Sciences) for 30 minutes at RT. After osmium fixation, organoids became dense relative to solutions and a centrifuge was not needed for further handling. Organoids were dehydrated in a graded ethanol series and then immersed in 50% hexamethyldisilazane (HMDS, Electron Microscopy Sciences) in 100% ethanol for 5 min and 100% HMDS for 10 min. Organoids in 0.3 mL of HMDS were aspirated using a transfer pipette and the solution and suspended organoids were deposited to 12 mm diameter SEM stubs coated with carbon adhesive tabs (Ted Pella Inc) and allowed to air dry. Samples were coated with gold using an Emitech K550X Sputter Coater and imaged with a Hitachi S3500 SEM operated at 5 kV.</p></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-10">RNA extraction and qRT-PCR</title><p hwp:id="p-14">Total RNA was isolated from cells or organoids using TRIzol. DNase I treatment was performed for 15 min at RT to remove contaminating DNA. cDNA synthesis was carried out using the TaqMan Reverse Transcription kit (Life Technologies) and random hexamers according to the manufacturer’s instructions. Quantitative Real time PCR (qRT- PCR) was performed using the Power SYBR Green Master Mix (Life Technologies). Cycling conditions were as follows: 15 min at 95 °C followed by 40 cycles of 15 sec at 94 °C, 30 sec at 60°C. <italic toggle="yes">Peptidylprolyl isomerase B</italic> (<italic toggle="yes">cyclophilin B</italic>) was used as an endogenous control in mouse and <italic toggle="yes">RPL13</italic> in human to normalize each sample and relative expression results were calculated using the 2<sup>-ΔΔCt</sup> method. A list of primers used is provided in Supplementary Table S1.</p></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-11">Subcellular localization</title><p hwp:id="p-15">For single-molecule FISH, cells were seeded onto acid-washed glass coverslips and fixed in 4% paraformaldehyde when reaching 50% confluency. RNA-FISH was carried out using the Affymetrix View ISH Cell Assay Kit and custom probes (Thermo Fisher) according to the manufacturer’s instructions. For human tissue, Pantomics BRC481 tissue microarrays were used. The slides were imaged on a LSM 710/780 confocal microscope (Zeiss). Cell fractionation assays were performed as described in (<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-4" hwp:rel-id="ref-13">13</xref>).</p></sec><sec id="s2f" hwp:id="sec-8"><title hwp:id="title-12">CRISPR/Cas promoter deletion</title><p hwp:id="p-16">To generate a genetic knockout, two sgRNAs targeting the promoter region were combined, creating a deletion. A sgRNA targeting the <italic toggle="yes">Renilla</italic> luciferase gene was used as non-targeting control. All sgRNAs were cloned into a lentiCRISPR_V2 plasmid (Addgene #52961) also encoding Cas9 and delivered to the cells using lentiviral transduction as described (<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>). Stable integrants were selected using puromycin selection and single cell sorted using a FACS Aria (SORP) Cell Sorter. Each single cell clone was propagated and analyzed by genomic PCR and qRT-PCR to select for homozygous knockout clones. Sequences for sgRNAs are provided in Supplementary Table S1.</p></sec><sec id="s2g" hwp:id="sec-9"><title hwp:id="title-13">Invasion assay</title><p hwp:id="p-17">Invasion assays were performed as described previously in (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-5" hwp:rel-id="ref-7">7</xref>). Briefly, a Cultrex® 96 well BME Cell Invasion Assay (Trevigen) was used. Cells were starved in FBS-free culture medium, then harvested and seeded at a density of 5 x 10<sup>4</sup> cells/well into the invasion chamber. ASOs were added to growth medium containing 10% FBS. The plate was incubated at 37 °C for 24 h and the assay was performed according to the manufacturer’s instructions. The fluorescence was measured with a SpectraMax i3 Multi- Mode Detection Platform (Molecular Devices) using the 480/520 nm filter set. Each sample was measured in triplicate.</p></sec><sec id="s2h" hwp:id="sec-10"><title hwp:id="title-14">Rescue Assay</title><p hwp:id="p-18"><italic toggle="yes">MaTAR20</italic> isoforms were amplified by PCR using Phusion High-Fidelity DNA Polymerase (NEB) following the manufacturer’s instructions. <italic toggle="yes">MaTAR20</italic> isoform 1 was cloned using Xhol and EcoRI-HF overhangs. The digested PCR product was ligated into a pCMV6-Entry plasmid (Origene) with T4 DNA ligase. Isoforms 2 and 3 were amplified by PCR, gel extracted and treated with T4 PNK. The pCMV6-Entry plasmid was digested using EcoRV-HF and Eco53kl followed by dephosphorylation using Quick CIP. Isoforms 2 and 3 were ligated into the pCMV6-Entry backbone as described above. Ligations were transformed into competent DH5α cells using heat shock. Transformants were selected for using Kanamycin at 25 µg/mL and validated using Sanger sequencing.</p><p hwp:id="p-19">For ectopic expression of <italic toggle="yes">MaTAR20</italic>, knockout cells were seeded into 96-well plates at a density of 5,000 cells/well. The plates were incubated overnight (16-18 h) at 37 °C with 5% CO2. DNA was transfected using Lipofectamine 2000 (Thermo Fisher) in serum-free DMEM medium at a ratio of 100 ng DNA : 0.2 µL Lipofectamine. After 6 h, the medium was replaced with 100 µL/well of fresh complete medium. Cells were fixed for each time point using 100 µL/well of staining solution (150 µg/mL saponin, 4 µg/mL DAPI, 0.5% PFA in PBS) for 30 minutes with gentle shaking at RT, then stored at 4 °C .The cells were counted using a Cytation5 automated cell counting system.</p><p hwp:id="p-20">RNA was isolated 24 h after transfection. The medium was removed and 50 µL of TRIzol was added to each well of a 96-well plate. RNA was extracted according to the manufacturer’s instructions. For each sample, 1 µg of RNA was treated with ezDNase and reverse transcribed to cDNA using SuperScript IV VILO following the manufacturer’s instructions (Thermo Fisher). For RT-qPCR testing of the <italic toggle="yes">MaTAR20</italic> rescue, PowerUp SYBR Green Master Mix (Thermo Fisher) was used. All RT-qPCRs were run on a QuantStudioTM 3 Real-Time PCR Machine (Applied Biosystems).</p></sec><sec id="s2i" hwp:id="sec-11"><title hwp:id="title-15"><italic toggle="yes">hMaTAR20</italic> CRISPR/Cas9 knockout cell lines</title><p hwp:id="p-21">T47D cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 0.2 Unit/mL human insulin and 1% penicillin/streptomycin. A sgRNA targeting the mouse <italic toggle="yes">MaTAR20</italic> gene was used as non-targeting control (M888). All sgRNAs were cloned into a lentiCRISPR_V2 plasmid (Addgene #52961) also encoding Cas9 and delivered to the cells using lentiviral transduction as described (<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-2" hwp:rel-id="ref-21">21</xref>). Stable integrants were selected using puromycin selection and single cell sorted using a FACS Aria (SORP) Cell Sorter. Each single cell clone was propagated and analyzed by genomic PCR and qRT-PCR to select for homozygous knockout clones (19bp deletion; hg38 chr9:137295224-137295246).</p></sec><sec id="s2j" hwp:id="sec-12"><title hwp:id="title-16">CRISPRi</title><p hwp:id="p-22">MDA-MB231-LM2 (LM2) cells (<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>) were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. We used lentiviral transduction to integrate dCas9 (pHAGE EF1α dCas9-KRAB, Addgene # 50919) as described (<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-3" hwp:rel-id="ref-21">21</xref>). A sgRNA targeting the <italic toggle="yes">Renilla</italic> luciferase gene was used as non-targeting control. sgRNAs targeting the promoter region of <italic toggle="yes">hMaTAR20</italic> (hg38 chr9:137295979-137295998 for -277; chr9: 137296113-137296128 for -390) were cloned into pLenti SpBsmBI Hygro plasmid (Addgene #62205) and delivered to the MDA-MB231-LM2-dCas9 cells using lentiviral transduction. Stable integrants were selected using hygromycin selection. For <italic toggle="yes">in vivo</italic> experiments 400,000 cells were xenografted into the L4 mammary fat pad of Nu/J mice (n=10 each for <italic toggle="yes">Ren</italic> control and <italic toggle="yes">hMaTAR20</italic> KD cells).</p></sec><sec id="s2k" hwp:id="sec-13"><title hwp:id="title-17">CRISPRa</title><p hwp:id="p-23">MCF10A cells were cultured in a media consisting of DMEM/F12 + GlutaMAX + 5% Horse Serum + 20 ng/ml EGF + 0.5 mg/ml Hydrocortisone + 100 ng/ml Cholera Toxin + 0.28 Units/ml Insulin. For CRISPR activation (CRISPRa) two plasmids carrying the components of the tagging system SUperNova (SunTag) were integrated into MCF10A cells by lentiviral transduction (<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>). The utilized plasmids were obtained from Addgene: pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS (#60904) and pLV-sgCDKN1B#2 BFP (#60903). All sgRNAs were cloned into the plasmid backbone pLenti SpBsmBI Hygro (Addgene #62205), and stable integrants were selected using hygromycin selection.</p></sec><sec id="s2l" hwp:id="sec-14"><title hwp:id="title-18">Proliferation assay</title><p hwp:id="p-24">The proliferation assay was performed by DAPI staining of the cell nuclei and automatically counted by a CytationTM 5 Cell Imaging Reader (BioTek). Briefly, cells were trypsinized and counted manually with a hemocytometer. One thousand cells per well were seeded into 10 wells of four 96-well plates. Cells were fixed and stained at 24 h, 48 h, 72 h, and 96 h post seeding with 100 μl staining solution (PBS, 150 ng/ml Saponin, 8 ng/ml DAPI, 0,5% PFA) per well for 30 minutes.</p></sec><sec id="s2m" hwp:id="sec-15"><title hwp:id="title-19">Scratch assay</title><p hwp:id="p-25">Scratch assays were performed following the protocol according to (<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>). Cells were trypsinized, seeded into a 24-well plate (or 6-well plates for MCF10A) and grown to full confluence. The cell monolayer was scratched using a 200 µL pipette tip to create a straight wound, followed by washing off floating cells with medium. Images were taken directly after scratching (T0) and after 24 h culturing (T24), and the rate of wound closure was calculated using Image J.</p></sec><sec id="s2n" hwp:id="sec-16"><title hwp:id="title-20">Animal experiments</title><p hwp:id="p-26">Animal experiments were carried out in the CSHL Animal Shared Resource, in accordance with IACUC approved procedures. MMTV-PyMT mice (<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>) were obtained from Dr. Mikala Egeblad (CSHL). Tumors and normal mammary glands were extracted immediately after euthanizing the animal and processed to generate primary cells, organoids or tissue sections. For <italic toggle="yes">in vivo</italic> ASO injections, female MMTV-PyMT mice were divided into two cohorts, being treated either with a <italic toggle="yes">MaTAR20</italic>-specific ASO or a scrambled control ASO at ∼8-10 weeks of age (after formation of palpable tumors). MOE ASOs were injected subcutaneously three times per week (n=4 for scASO, n=5 for <italic toggle="yes">MaTAR20</italic> ASO). cET ASOs were injected twice per week, both at 50 mg/kg per dose (n=7 for scASO, n=7 for <italic toggle="yes">MaTAR20</italic> ASO). Tumors were measured twice per week throughout the treatment course. At the end of the experiment, mice were euthanized, and primary tumors and lungs were fixed in 4% PFA and embedded in paraffin for histo- pathological analysis, or snap-frozen for RNA extractions. FFPE blocks were sectioned and stained with hematoxylin and eosin (H&amp;E). Slides were scanned and analyzed using the Aperio ImageScope software. Immunohistochemistry was performed using the following antibodies: Tnfsf15 (Bioss, BS-5092R), Anti-Ki67 (AbCam, ab15580), Cleaved Caspase-3 (Cell Signaling, 9661), VegfB (Invitrogen, PA5-80220), VegfA (AbCam, ab1316). The resulting images were analyzed using QuPath software v0.2.3(<xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref>).</p></sec><sec id="s2o" hwp:id="sec-17"><title hwp:id="title-21">RNA-seq</title><p hwp:id="p-27">RNA quality was assessed on an Agilent 2100 Bioanalyzer. Libraries were prepared on samples with RIN ≥9 using the Illumina TruSeq sample prep kit v2 and sequenced on an Illumina NextSeq instrument. Data was analyzed as previously described (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-6" hwp:rel-id="ref-7">7</xref>). Briefly, the quality of FASTQ files was assessed using FastQC (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" hwp:id="ext-link-2">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>). Reads were mapped to GRCm38 using STAR (<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>), and the reads per gene record were counted using HTSeq- count (<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>). Differential gene expression was performed with DESeq2 (<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>), and an adjusted p-value of &lt; 0.05 was set as threshold for statistical significance. KEGG pathway and GO term enrichment and was carried out using the R/Bioconductor packages GAGE (<xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>) and Pathview (<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>).</p></sec><sec id="s2p" hwp:id="sec-18"><title hwp:id="title-22">ChIRP-seq</title><p hwp:id="p-28">ChIRP-seq was carried out as previously described (<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-5" hwp:rel-id="ref-13">13</xref>). Briefly, 20 million cells were harvested and fixed in 1% glutaraldehyde solution. ChIRP was performed using two individual tiling pools of biotinylated oligonucleotide probes. A probe pool targeting mouse <italic toggle="yes">Ppib</italic> was used as negative control. A list of ChIRP-seq probes is provided in Supplementary Table S1. ChIRP-Seq libraries were generated using the Illumina TruSeq ChIP Library Preparation Kit and sequenced on an Illumina NextSeq instrument. ChIRP- seq data quality was assessed using FastQC (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/" hwp:id="ext-link-3">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) and paired-end reads were mapped to GRCm38 using Bowtie2 (<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>). ChIRP-seq analysis was performed using HOMER (<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>). For RT-qPCRs testing the ChIRP cDNA, 5 ng cDNA and 5 µM of primers in 10 µL was used (reagents and cycling conditions as described under “Rescue assay”).</p></sec><sec id="s2q" hwp:id="sec-19"><title hwp:id="title-23">Data access</title><p hwp:id="p-29">RNA-seq and ChIRP-seq data have been deposited at Gene Expression Omnibus (GEO) under accession number GSE171085.</p></sec></sec><sec id="s3" hwp:id="sec-20"><title hwp:id="title-24">Results</title><sec id="s3a" hwp:id="sec-21"><title hwp:id="title-25"><italic toggle="yes">MaTAR20</italic> is a tumor-specific, nuclear-retained lncRNA</title><p hwp:id="p-30"><italic toggle="yes">MaTAR20</italic> is an intergenic lncRNA gene located on mouse chromosome 2. According to GENCODE vM18, three isoforms of the <italic toggle="yes">MaTAR20</italic> transcript exist, comprising 2,646, 659 and 638 nt (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1A</xref>). Our computational analysis of ENCODE expression data revealed that the lncRNA is absent or expressed at low levels in normal mammary glands and other normal tissues, but highly expressed (FPKM &gt;200) in mammary tumors derived from the transgenic MMTV-PyMT mouse model of luminal BC (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1B</xref>). Furthermore, <italic toggle="yes">MaTAR20</italic> levels correlate with tumor size in the MMTV-PyMT model (Supplementary Figure S1A).</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4 xref-fig-1-5 xref-fig-1-6 xref-fig-1-7 xref-fig-1-8 xref-fig-1-9 xref-fig-1-10 xref-fig-1-11 xref-fig-1-12 xref-fig-1-13"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1:</label><caption hwp:id="caption-1"><title hwp:id="title-26"><italic toggle="yes">MaTAR20</italic> is a tumor-specific, nuclear-retained lncRNA</title><p hwp:id="p-31"><bold>A:</bold> Schematic overview of the <italic toggle="yes">MaTAR20</italic>/<italic toggle="yes">Gm13387</italic> locus (UCSC Browser, mm10) GENCODE vM18 annotation in green.</p><p hwp:id="p-32"><bold>B:</bold> Abundance (FPKM) of <italic toggle="yes">MaTAR20</italic> in ENCODE mouse tissue and HER2+ mammary tumors.</p><p hwp:id="p-33"><bold>C:</bold> Single molecule RNA FISH of MaTAR20 in primary MMTV-PyMT cells. Top panel: merge, middle panel: MaTAR20 (red), bottom panel: DAPI (blue).</p><p hwp:id="p-34"><bold>D:</bold> Cellular fractionation assay followed by qRT-PCR.</p><p hwp:id="p-35"><bold>E:</bold> ASO-mediated knockdown of MaTAR20 in primary MMTV-PyMT organoids. Two specific ASOs were tested for MaTAR20, and a scASO was used as negative control. Bars denote the mean of at least two biological replicates +/- SD.</p><p hwp:id="p-36"><bold>F:</bold> Quantification of organoid branching upon MaTAR20 knockdown. Bars denote the mean of at least three biological replicates +/- SD.</p><p hwp:id="p-37"><bold>G:</bold> Exemplarily images of organoids quantified in F.</p><p hwp:id="p-38"><bold>H:</bold> Exemplarily SEM micrograph of organoids quantified in F.</p></caption><graphic xlink:href="437774v3_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><p hwp:id="p-39">To examine the localization of <italic toggle="yes">MaTAR20</italic> we performed single molecule RNA-FISH in primary MMTV-PyMT cells (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figure 1C</xref>). Our results indicate that <italic toggle="yes">MaTAR20</italic> is indeed an abundant lncRNA in primary mammary tumor cells, and predominantly localizes to the nucleus, averaging 10-40 foci per nucleus. We further confirmed that <italic toggle="yes">MaTAR20</italic> is a nuclear-retained transcript by subcellular fractionation assays, which revealed an enrichment in both the nucleoplasm and the chromatin fractions (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Figure 1D</xref>), a localization pattern comparable to the lncRNA <italic toggle="yes">Malat1</italic>. Our initial characterization indicates that <italic toggle="yes">MaTAR20</italic> is a tumor-specific, nuclear-enriched lncRNA that may play a role in tumor progression based on its expression profile.</p></sec><sec id="s3b" hwp:id="sec-22"><title hwp:id="title-27">Knockdown of <italic toggle="yes">MaTAR20</italic> leads to reduced organoid branching</title><p hwp:id="p-40">To determine if <italic toggle="yes">MaTAR20</italic> is a driver of mammary tumor cell growth, we performed knockdown experiments <italic toggle="yes">ex vivo</italic>, in MMTV-PyMT derived tumor organoids (<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-2" hwp:rel-id="ref-6">6</xref>,<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-7" hwp:rel-id="ref-7">7</xref>,<xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>) (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-5" hwp:rel-id="F1">Figure 1E-H</xref>). Organoids are an excellent model system to study cancer biology and to test new therapeutic treatments (for review, see (<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>)). Wildtype/untreated organoids exhibit a branched morphology consistent with collective cell migration (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-6" hwp:rel-id="F1">Fig 1G-H</xref>) and/or proliferation (for review, see (<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>). We achieved <italic toggle="yes">MaTAR20</italic> knockdown efficiencies of 50- 60% using 2’-O-methoxyethyl (MOE) ASOs in 3D mammary tumor organoids by free uptake (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-7" hwp:rel-id="F1">Figure 1E</xref>). Treatment of MMTV-PyMT tumor organoids with two independent MOE ASOs targeting <italic toggle="yes">MaTAR20</italic> lead to an up to 40% reduction of organoid branching compared to untreated organoids, or organoids treated with a scrambled control MOE ASO (scASO) (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-8" hwp:rel-id="F1">Figure 1F-H</xref>). Based on these and our previous results in primary mammary epithelial cells (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-8" hwp:rel-id="ref-7">7</xref>), we conclude that <italic toggle="yes">MaTAR20</italic> enhances both the proliferative and migratory potential of mammary tumor cells.</p></sec><sec id="s3c" hwp:id="sec-23"><title hwp:id="title-28">Promoter deletion of <italic toggle="yes">MaTAR20</italic> results in a less aggressive phenotype</title><p hwp:id="p-41">To independently validate our ASO-mediated knockdown results, and to develop a model system that enables us to study the molecular mechanism of <italic toggle="yes">MaTAR20</italic> in detail, we generated <italic toggle="yes">MaTAR20</italic> loss-of-function cells using the CRISPR/Cas9 system. First, we tested a panel of mouse mammary tumor cell lines to identify a suitable model system. Of the tested cell lines, the metastatic 4T1 line (<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>) showed the highest <italic toggle="yes">MaTAR20</italic> expression level (Supplementary Figure S2A). Next, we established promoter deletion of <italic toggle="yes">MaTAR20</italic> by stably integrating Cas9 and two guide RNAs (gRNAs): the first gRNA was designed to bind upstream of the <italic toggle="yes">MaTAR20</italic> transcription start site (at -736) and the second gRNA binding within the first exon of <italic toggle="yes">MaTAR20</italic> (+12 bp) (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2A</xref>), resulting in promoter deletion of 748 bp. A gRNA targeting the <italic toggle="yes">Renilla</italic> luciferase gene was used to generate negative control cells. All edited cell populations were single cell sorted to generate monoclonal cell lines. Two <italic toggle="yes">MaTAR20</italic> knockout clones (KO1, KO2) and two negative control clones (Ren1, Ren2) were analyzed further. The KO cell lines showed a ∼80-85% reduction of <italic toggle="yes">MaTAR20</italic> expression compared to control clones (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2B</xref>). We used four different primer pairs to measure <italic toggle="yes">MaTAR20</italic> levels, one amplifying all three isoforms of <italic toggle="yes">MaTAR20</italic> (PP1, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2B</xref>), and three isoform-specific primer pairs (PP2, PP3, PP4; Supplementary Figure S2B). Our results indicate that all three isoforms of <italic toggle="yes">MaTAR20</italic> were reduced to comparable levels in the KO cells.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5 xref-fig-2-6 xref-fig-2-7 xref-fig-2-8 xref-fig-2-9 xref-fig-2-10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2:</label><caption hwp:id="caption-2"><title hwp:id="title-29"><italic toggle="yes">MaTAR20</italic> KO cells show reduced proliferation and cell adhesion</title><p hwp:id="p-42">Statistical significance was determined with a two-way ANOVA; * p &lt; 0.05, ** p &lt; 0.01. <bold>A:</bold> Schematic overview of the knockout strategy. Guide RNAs (gRNAs) are indicated in red, +/- indicate genomic position relative to the <italic toggle="yes">MaTAR20</italic> transcription start site.</p><p hwp:id="p-43"><bold>B</bold>: qRT-PCR to determine relative <italic toggle="yes">MaTAR20</italic> expression in <italic toggle="yes">MaTAR20</italic> promoter deletion cell lines. KO = promoter deletion of 748 bp (combination of gRNAs “+12” and “-736”), Ren = negative control, integration of Cas9 and a gRNA targeting <italic toggle="yes">Renilla</italic> luciferase. Bars denote the mean of at least six biological replicates +/- SEM.</p><p hwp:id="p-44"><bold>C</bold>: Cell proliferation assay. Number of cells determined after 24, 48 and 72h. Data points denote the mean of at least two biological replicates +/- SEM.</p><p hwp:id="p-45"><bold>D:</bold> Cell cycle profiles of NST-DAPI stained cells, comparing Ren control cells to KO1 and KO2.</p><p hwp:id="p-46"><bold>E:</bold> Scanning electron micrograph of control (Ren) or CRISPR/Cas9-modified cells (KO). Scale as indicated.</p></caption><graphic xlink:href="437774v3_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-47">Similar to our ASO-mediated knockdown experiments in primary mammary tumor cells (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-9" hwp:rel-id="ref-7">7</xref>), we observed a 30-40% reduction of cell proliferation in the KO cell lines (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2C</xref>). This phenotype was not caused by differences in cell cycle profiles (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Figure 2D</xref>) and did not correlate with Cas9 expression (Supplementary Figure S2C). Ectopic expression of <italic toggle="yes">MaTAR20</italic> in KO cells was able to rescue the cell proliferation phenotype, restoring growth rates to levels comparable to Ren control cells (Supplementary Figure S3A-B). This finding also indicates that the <italic toggle="yes">MaTAR20</italic> transcript is responsible for the observed phenotype, rather than the genomic locus itself playing a regulatory role and that <italic toggle="yes">MaTAR20</italic> plays a role in <italic toggle="yes">trans</italic>.</p><p hwp:id="p-48">While culturing the <italic toggle="yes">MaTAR20</italic> KO cells, we noticed a difference in cell adhesion between the KO clones and the control cell lines. The KO cells were particularly difficult to dislodge from cell culture flasks, leading to increased (2-4 fold) trypsinization times required to detach the KO cells. Further examination of the KO and Ren control cells using scanning electron microscopy revealed that reduced <italic toggle="yes">MaTAR20</italic> levels may lead to stronger surface attachment of the cells, accompanied by more organized, sheet-like structures (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-6" hwp:rel-id="F2">Figure 2E</xref>). In summary, promoter deletion of <italic toggle="yes">MaTAR20</italic> leads to reduced tumor cell growth and migration compared to control cells, similar to primary cells treated with <italic toggle="yes">MaTAR20</italic> ASOs (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-9" hwp:rel-id="F1">Figure 1</xref>).</p></sec><sec id="s3d" hwp:id="sec-24"><title hwp:id="title-30">The human orthologue, <italic toggle="yes">hMaTAR20,</italic> drives breast cancer cell growth</title><p hwp:id="p-49">We previously identified the human orthologue of <italic toggle="yes">MaTAR20</italic>, <italic toggle="yes">hMaTAR20</italic>, by synteny as <italic toggle="yes">RP13-122B23.8 (ENSG00000260996</italic>), located on chromosome 9 (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-10" hwp:rel-id="ref-7">7</xref>). To investigate whether <italic toggle="yes">hMaTAR20</italic> drives breast cancer cell growth and therefore may hold clinical significance, we first performed computational analyses of <italic toggle="yes">hMaTAR20</italic> expression of TCGA data. The lncRNA is overexpressed 2-fold across all subtypes of breast cancer compared to adjacent normal breast tissue, with highest levels in estrogen receptor positive (ER+) breast cancer (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3A</xref>). RNA-FISH on a tissue microarray further confirmed a 2-fold up-regulation of <italic toggle="yes">hMaTAR20</italic> in breast cancer compared to corresponding normal tissue (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3B</xref>). Further stratifying the breast cancer tissue revealed highest levels of <italic toggle="yes">hMaTAR20</italic> in grade II-III tumors (Supplementary Figure S4A), following a similar trend of increased expression in later stage tumors as observed in mouse (Supplementary Figure S1).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4 xref-fig-3-5 xref-fig-3-6 xref-fig-3-7 xref-fig-3-8 xref-fig-3-9"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3:</label><caption hwp:id="caption-3"><title hwp:id="title-31">Human <italic toggle="yes">MaTAR20</italic> (<italic toggle="yes">hMaTAR20</italic>) drives cell proliferation and migration</title><p hwp:id="p-50">Bars denote the mean of three biological replicates +/- SEM. * p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001.</p><p hwp:id="p-51"><bold>A:</bold> Analysis of <italic toggle="yes">hMaTAR20</italic> expression in TCGA data, by subtype. LumA = luminal A, LumB = luminal B, NL = normal-like breast cancer.</p><p hwp:id="p-52"><bold>B:</bold> RNA-FISH of <italic toggle="yes">hMaTAR20</italic> on a tissue microarray (TMA), comparing expression in breast cancer to corresponding normal breast tissue.</p><p hwp:id="p-53"><bold>C:</bold> qRT-PCR to determine relative <italic toggle="yes">hMaTAR20</italic> expression in CRISPR/Cas9 edited T47D cells. M888: control cell line with non-targeting sgRNA. KO C9 and KO V2: individual single cell sorted colonies of T47D cells with a deletion in exon 1.</p><p hwp:id="p-54"><bold>D:</bold> Cell proliferation assay comparing growth curves of the M888 negative control to the two <italic toggle="yes">hMaTAR20</italic> KO clones.</p><p hwp:id="p-55"><bold>E:</bold> Left: quantification of T47D spheroid branching (left). Right: exemplary images of the negative control M888 (top) and the KO C2 clone (bottom). For each biological replicate, n = 100 spheroids were analyzed (n = 300, total).</p><p hwp:id="p-56"><bold>F:</bold> Quantification of T47D scratch assay.</p><p hwp:id="p-57"><bold>G:</bold> qRT-PCR to determine relative <italic toggle="yes">hMaTAR20</italic> expression in MCF10A cells. The endogenous <italic toggle="yes">hMaTAR20</italic> gene was up-regulated using CRISPRa using three specific sgRNAs: -200, -270 and -390 (numbers denote the distance from the TSS). A non- targeting sgRNA for <italic toggle="yes">Renilla</italic> luciferase served as a negative control (Ren).</p><p hwp:id="p-58"><bold>H:</bold> Cell proliferation assay comparing growth curves of the Ren negative control to the three <italic toggle="yes">hMaTAR20</italic> CRISPRa cell lines.</p><p hwp:id="p-59"><bold>I:</bold> Quantification of MCF10A scratch assay.</p></caption><graphic xlink:href="437774v3_fig3" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-60">We performed an expression screen in several breast cancer cell lines, which further confirmed that ER+ cell lines show increased levels of <italic toggle="yes">hMaTAR20</italic> (Supplementary Figure S4B), with T47D showing the highest levels. Therefore, we generated a CRISPR/Cas9 driven deletion in exon 1 in T47D cells, which resulted in stable reduction of <italic toggle="yes">hMaTAR20</italic> levels (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3C</xref>) in two single cell clone derived cell lines (KO C9 and KO V2). Lower <italic toggle="yes">hMaTAR20</italic> levels lead to reduced cell proliferation in T47D KO cells compared to control cells grown in 2D culture and reduced branching in spheroid culture, with more pronounced effects in the 3D assay (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Figure 3D-E</xref>). We also observed reduced 2D migration in <italic toggle="yes">hMaTAR20</italic> KO cells (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-5" hwp:rel-id="F3">Figure 3F</xref>). Like <italic toggle="yes">MaTAR20</italic> in mouse, <italic toggle="yes">hMaTAR20</italic> showed predominantly nuclear localization (Supplementary Figure S4C), suggesting the lncRNA functions similarly in both organisms.</p><p hwp:id="p-61">While <italic toggle="yes">hMaTAR20</italic> expression is highest in ER+ breast cancer, the lncRNA is also overexpressed in all other types of breast cancer compared to adjacent normal tissue. To study the impact of <italic toggle="yes">hMaTAR20</italic> in an ER- model, we generated a CRISPR interference (CRISPRi) driven transcriptional repression model of <italic toggle="yes">hMaTAR20</italic> in the aggressive basal cell line MDA-MB-231-LM2 (<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-2" hwp:rel-id="ref-22">22</xref>)(Supplementary Figure S4D). Similar to the T47D KO cells, we observed reduced cell proliferation, spheroid branching and cell migration in the MDA-MB-231-LM2 CRISPRi model (Supplementary Figure S4E-G).</p><p hwp:id="p-62">Next, we tested whether increasing <italic toggle="yes">hMaTAR20</italic> levels in the pre-malignant cell line MCF10A may lead to an increase in proliferative and migratory potential. MCF10A cells express <italic toggle="yes">hMaTAR20</italic> at very low levels compared to T47D or MDA-MB-231-LM2 cells (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-6" hwp:rel-id="F3">Figure 3B</xref>). Using CRISPR activation (CRISPRa), we up-regulated endogenous <italic toggle="yes">hMaTAR20</italic> expression using three different sgRNAs (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-7" hwp:rel-id="F3">Figure 3G</xref>). We observed increased cell proliferation and viability as well as increased migration compared to control cells (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-8" hwp:rel-id="F3">Figure 3H-I</xref>). In summary, our results show that <italic toggle="yes">hMaTAR20</italic> is a driver of cell proliferation and migration in human breast cancer cells, recapitulating the phenotype we observed with <italic toggle="yes">MaTAR20</italic> in the mouse system.</p></sec><sec id="s3e" hwp:id="sec-25"><title hwp:id="title-32">cET ASO shows improved knockdown efficiency <italic toggle="yes">in vitro</italic></title><p hwp:id="p-63">To determine the effect of <italic toggle="yes">MaTAR20</italic> reduction on tumor progression, and to investigate whether ASOs are a viable strategy to systemically reduce <italic toggle="yes">MaTAR20</italic>, we performed <italic toggle="yes">in vivo</italic> experiments in transgenic mouse models of breast cancer. First, we designed a constrained ethyl (cET) ASO targeting <italic toggle="yes">MaTAR20</italic>. In comparison to MOE ASOs (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-10" hwp:rel-id="F1">Figure 1</xref>), cET ASOs show increased potency <italic toggle="yes">in vivo</italic> (<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>) and are the chemistry of choice for tissues less sensitive to ASO modulation with several clinical trials currently ongoing (<xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>).</p><p hwp:id="p-64">Before introducing the cET ASO into animals, we tested its knockdown (KD) efficiency <italic toggle="yes">in vitro</italic>. Concentrations as low as 250 nM were sufficient to achieve &gt;60% knockdown of <italic toggle="yes">MaTAR20</italic> within 24 h in 4T1 cells (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 4A</xref>), and we observed KD efficiencies of &gt;95% using 500 nM after 72 h (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Figure 4B</xref>). These results compare favorably to concentrations of 4-5 µM of MOE ASOs achieving ∼50% KD in organoids (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-11" hwp:rel-id="F1">Figure 1</xref>) and ∼70% KD in primary cells (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-11" hwp:rel-id="ref-7">7</xref>). Knockdown of <italic toggle="yes">MaTAR20</italic> using the cET ASO resulted in significantly reduced cell proliferation and invasion (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-3" hwp:rel-id="F4">Figure 4C-D</xref>), however, it is possible that the difference in proliferation impacts on the readout of the invasion assay as well. These results agree with our observations using MOE ASOs (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-12" hwp:rel-id="F1">Figure 1</xref>) and <italic toggle="yes">MaTAR20</italic> promoter deletions in mouse (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-7" hwp:rel-id="F2">Figure 2</xref>) as well as our findings for <italic toggle="yes">hMaTAR20</italic> (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-9" hwp:rel-id="F3">Figure 3</xref>).</p><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3 xref-fig-4-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4:</label><caption hwp:id="caption-4"><title hwp:id="title-33">cET ASO-mediated knockdown of <italic toggle="yes">MaTAR20</italic> in 4T1 cells lead to reduced cell proliferation and invasion</title><p hwp:id="p-65">Bars denote the mean of three biological replicates +/- SEM. Statistical significance was determined with a two-tailed Student’s t-test; * p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001.</p><p hwp:id="p-66"><bold>A:</bold> qRT-PCR to determine relative <italic toggle="yes">MaTAR20</italic> expression. 24 h post treatments with cET ASOs (concentrations as indicated).</p><p hwp:id="p-67"><bold>B:</bold> qRT-PCR to determine relative <italic toggle="yes">MaTAR20</italic> expression. 72 h post treatments with 0.5 µM cET ASOs.</p><p hwp:id="p-68"><bold>C:</bold> Proliferation assay. Cells were counted 24 h and 72 h post treatment with 0.5 µM cET ASOs.</p><p hwp:id="p-69"><bold>D:</bold> Invasion assay. Fluorescence units 24 h post treatment with 0.5 µM cET ASOs.</p></caption><graphic xlink:href="437774v3_fig4" position="float" orientation="portrait" hwp:id="graphic-4"/></fig></sec><sec id="s3f" hwp:id="sec-26"><title hwp:id="title-34">Knockdown of <italic toggle="yes">MaTAR20 in vivo</italic> leads to a reduction in tumor growth and induces tumor necrosis</title><p hwp:id="p-70">To further investigate the potential of cET ASOs targeting <italic toggle="yes">MaTAR20</italic> in mammary tumors, we injected 100 mg/kg/week of either <italic toggle="yes">MaTAR20</italic> cET or a negative control ASO (scrambled = scASO cET) into MMTV-PyMT (C57BL/6) mice after palpable tumor formation (n=7 for scASO, n=8 for <italic toggle="yes">MaTAR20</italic> ASO; <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5A</xref>). We achieved an 80% reduction of <italic toggle="yes">MaTAR20</italic> in the tumors on average, further highlighting the potency of the cET chemistry (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 5B</xref>). We initiated ASO injections on animals with comparable average tumor burden in both cohorts and observed a 30% overall reduced tumor burden in <italic toggle="yes">MaTAR20</italic> cET treated mice over the course of eight weeks (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Figure 5C</xref>). While mice in the <italic toggle="yes">MaTAR20</italic> cET group eventually went on to develop tumors, tumor onset was delayed in comparison to the scASO cET group. Furthermore, when comparing the growth curves of similarly sized tumors that developed at the same time in both cohorts, tumors in the <italic toggle="yes">MaTAR20</italic> cET group grew slower compared to scASO cET treated mice, resulting in a difference of 75% after 8 weeks (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figure 5D</xref>). After all mice reached the study endpoint, we carried out hematoxylin and eosin (H&amp;E) staining of the fixed tumors to investigate potential histo-pathological differences. Notably, tumors in the <italic toggle="yes">MaTAR20</italic> cET treated group showed severe necrosis compared to the control group (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Figure 5E</xref>).</p><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6 xref-fig-5-7 xref-fig-5-8 xref-fig-5-9 xref-fig-5-10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5:</label><caption hwp:id="caption-5"><title hwp:id="title-35">cET ASO-mediated knockdown of <italic toggle="yes">MaTAR20 in vivo</italic> lead to reduced tumor growth and metastatic burden</title><p hwp:id="p-71">Statistical significance was determined with a two-tailed Student’s t-test; * p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001.</p><p hwp:id="p-72"><bold>A:</bold> MMTV-PyMT (C57/Bl6) mice were treated for 8 weeks with cET ASOs (100 mg/kg/week), either scASO (cET) or <italic toggle="yes">MaTAR20</italic> cET1. Bars / lines denote the mean of biological replicates +/- SEM. N= 33 tumors from 7 mice for scASO (cET); n = 26 tumors from 8 mice for <italic toggle="yes">MaTAR20</italic> cET1.</p><p hwp:id="p-73"><bold>B:</bold> qRT-PCR to determine relative <italic toggle="yes">MaTAR20</italic> expression in tumors. <bold>C:</bold> Average number of tumors per mouse in each treatment group. <bold>D:</bold> Average tumor burden in mm<sup>3</sup> per week in each treatment group.</p><p hwp:id="p-74"><bold>E:</bold> Hematoxylin and Eosin staining of tumor sections. Top left: scASO (cET) treated tumor (whole tumor). Top right: scASO (cET) treated tumor, 10x. Bottom left: <italic toggle="yes">MaTAR20</italic> cET1 treated tumor (whole tumor). Bottom right: <italic toggle="yes">MaTAR20</italic> cET1 treated tumor, 10x.</p><p hwp:id="p-75"><bold>F:</bold> Tumor growth curves of MDA-MB-231-LM2 cells were xenografted into nude mice. Ren: a non-targeting negative control (n=10); -277: <italic toggle="yes">hMaTAR20</italic> CRISPRi cell line (n=9). Data points denote the mean of biological replicates +/- SEM.</p><p hwp:id="p-76"><bold>G:</bold> Quantification of tumor necrosis, based on H&amp;E staining. Bars denote the mean of three biological replicates +/- SEM.</p></caption><graphic xlink:href="437774v3_fig5" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><p hwp:id="p-77">To confirm that the human orthologue of <italic toggle="yes">MaTAR20</italic> acts similarly to the mouse lncRNA in an <italic toggle="yes">in vivo</italic> situation, we xenografted one of our loss-of-function models, the modified MDA-MB-231-LM2 cells into the mammary fat pad of nude mice. We observed reduced tumor growth and increased tumor necrosis (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Figure 5F-G</xref>), further confirming the functional role of the <italic toggle="yes">hMaTAR20</italic> in tumor progression.</p></sec><sec id="s3g" hwp:id="sec-27"><title hwp:id="title-36">Knockdown of <italic toggle="yes">MaTAR20 in vivo</italic> leads to reduced metastatic burden</title><p hwp:id="p-78">The MMTV-PyMT model is highly aggressive, with a metastasis incidence rate of &gt;80% (<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-2" hwp:rel-id="ref-25">25</xref>). We examined the lungs in our <italic toggle="yes">in vivo</italic> study post-mortem for macro-metastatic nodules. While 7/7 mice in the scASO group developed at least one macro-metastatic nodule, only 4/7 mice in the <italic toggle="yes">MaTAR20</italic> ASO cohort presented macro-metastatic lesions (Supplementary Figure S5A). We went on to examine the histo-pathology of the four lungs that developed metastasis by H&amp;E staining and discovered that metastases in the <italic toggle="yes">MaTAR20</italic> ASO treated group showed cystic, differentiated nodules compared to the solid masses detected in the scASO cohort (Supplementary Figure S5B-C). We suggest that metastatic nodules in animals that received the <italic toggle="yes">MaTAR20</italic> cET may have developed prior to treatment start, and that the cystic phenotype is a consequence of systemic <italic toggle="yes">MaTAR20</italic> knockdown, impacting already existing metastases. Alternatively, the observed differences could be due to reduced overall tumor burden.</p><p hwp:id="p-79">To independently validate our animal studies, we performed a second <italic toggle="yes">in vivo</italic> experiment using <italic toggle="yes">MaTAR20</italic> MOE ASO1 and injected it into MMTV-PyMT (FVB) mice (Supplementary Figure S5D). Similar to the cET experiments in C57/Bl6, we observed reduced tumor growth for the <italic toggle="yes">MaTAR20</italic> ASO group compared to the scASO group from around week 4 of treatment (Supplementary Figure S5E). H&amp;E staining of tumor sections revealed that animals in the <italic toggle="yes">MaTAR20</italic> MOE group also developed more necrotic tumors compared to control animals (Supplementary Figure S5G). In addition, we observed a reduction of macro-metastatic nodules in the lungs of 3/4 mice receiving <italic toggle="yes">MaTAR20</italic> MOE ASO1 (Supplementary Figure S5F), confirming the trend of reduced metastasis upon <italic toggle="yes">MaTAR20</italic> knockdown.</p><p hwp:id="p-80">Immunohistochemistry staining of the tumor sections for Ki67 revealed slightly reduced levels in both MOE and cET cohorts. We did not observe a consistent trend when staining for the apoptosis marker cleaved caspase 3, indicating that the tumors likely undergo necrosis rather than programmed cell death (Supplementary Figure S6A-B). In summary, our <italic toggle="yes">in vivo</italic> experiments show that systemic reduction of <italic toggle="yes">MaTAR20</italic> using ASOs leads to delayed mammary tumor onset, reduced tumor growth, increased tumor necrosis and reduced metastasis.</p></sec><sec id="s3h" hwp:id="sec-28"><title hwp:id="title-37"><italic toggle="yes">MaTAR20</italic> expression level correlates with VEGF expression</title><p hwp:id="p-81">We set out to identify the molecular mechanism by which <italic toggle="yes">MaTAR20</italic> impacts tumor cell growth and invasion. As our RNA-FISH and subcellular fractionation assays indicated that <italic toggle="yes">MaTAR20</italic> is a nuclear-retained lncRNA (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-13" hwp:rel-id="F1">Figure 1</xref>), we hypothesized that it may act by impacting gene expression. First, we performed a computational co-expression analysis using lncRNA2function (<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>). Similar approaches have been previously applied successfully to identify the molecular role of other lncRNAs (<xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>). Notably, we observed a strong enrichment for pathways involved in angiogenesis, with the top 7 most enriched pathways being related to vascular endothelial growth factor (VEGF) signaling (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 6A</xref>), including “Signaling by VEGF”, “VEGF hypoxia and angiogenesis” and “Sorafenib Pharmacodynamics”, a multi-kinase inhibitor that has been shown to act on VEGF receptor (VEGFR) (<xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>). Due to this striking ontology enrichment, we set out to experimentally assess if <italic toggle="yes">MaTAR20</italic> and VEGF expression correlate. We determined by qRT-PCR that Vegf-A and Vegf-B are reduced in tumors of MMTV-PyMT mice that received the <italic toggle="yes">MaTAR20</italic> cET ASO compared to the scASO control group (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 6B</xref>). Immunohistochemistry staining of tumor sections confirmed this trend on the protein level (Supplementary Figure S6C-D). We also assayed CD31 staining in the tumors to probe for differences in angiogenesis and observed reduced CD31+ cells in <italic toggle="yes">MaTAR20</italic> ASO treated animals (Supplementary Figure S6E), which may point to a reduced number of blood vessels being formed upon <italic toggle="yes">MaTAR20</italic> loss.</p><fig id="fig6" position="float" orientation="portrait" fig-type="figure" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3 xref-fig-6-4 xref-fig-6-5 xref-fig-6-6 xref-fig-6-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Figure 6:</label><caption hwp:id="caption-6"><title hwp:id="title-38"><italic toggle="yes">MaTAR20</italic> impacts VEGF expression</title><p hwp:id="p-82">Statistical significance was determined with a two-tailed Student’s t-test; * p &lt; 0.05, ** p &lt; 0.01.</p><p hwp:id="p-83"><bold>A:</bold> Co-expression analysis to identify <italic toggle="yes">MaTAR20</italic> associated pathways. The 15 most significant pathways are shown.</p><p hwp:id="p-84"><bold>B:</bold> qRT-PCR to determine the relative Vegf-A and Vegf-B expression in tumors. MMTV- PyMT mice were treated for 8 weeks with cET ASOs (100 mg/kg/week), either scASO (cET) or <italic toggle="yes">MaTAR20</italic> cET1.</p><p hwp:id="p-85"><bold>C:</bold> qRT-PCR to determine the relative Vegf-B expression in 4T1 cells. 72 h post treatments with 0.5 µM cET ASOs. Bars denote the mean of three biological replicates +/- SEM.</p><p hwp:id="p-86"><bold>D:</bold> qRT-PCR to determine the relative Vegf-B expression in <italic toggle="yes">MaTAR20</italic> KO cells. Bars denote the mean of two biological replicates +/- SEM.</p></caption><graphic xlink:href="437774v3_fig6" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><p hwp:id="p-87">We used RNA extracted from whole tumors for the qRT-PCR validations described above. While MMTV-PyMT tumors generally contain a high percentage of cancer cells (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-7" hwp:rel-id="F5">Figure 5E</xref>, Supplementary Figure S5E), qRT-PCR from whole tumors cannot distinguish between expression changes in tumor or stromal cells. To investigate whether VEGF expression was reduced in the same cell type as <italic toggle="yes">MaTAR20</italic>, we measured VEGF expression in 4T1 cells with successful <italic toggle="yes">MaTAR20</italic> KD (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-4" hwp:rel-id="F4">Figure 4A</xref>/B). Indeed, we observed a 35% reduction of Vegf-B (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 6C</xref>), while Vegf-A was not expressed at levels sufficient for reliable qPCR detection in these cells (Ct &gt; 30). We also tested Vegf-B expression in our three knockout cell lines (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-8" hwp:rel-id="F2">Figure 2</xref>), and observed a statistically significant, 40-60% down-regulation of Vegf-B compared to control cells (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-4" hwp:rel-id="F6">Figure 6D</xref>). Upon ectopic expression of <italic toggle="yes">MaTAR20</italic> in the KO cells, Vegf-B levels were up-regulated (Supplementary Figure S7A). Based on convergent results obtained from four independent experiments (ASO KD <italic toggle="yes">in vitro</italic>, <italic toggle="yes">in vivo</italic>, CRISPR/Cas9 promoter deletions and rescue assays), we conclude that down-regulation of <italic toggle="yes">MaTAR20</italic> correlates with reduced VEGF expression levels and may be associated with reduced tumor angiogenesis.</p></sec><sec id="s3i" hwp:id="sec-29"><title hwp:id="title-39"><italic toggle="yes">MaTAR20</italic> loss leads to alterations in cancer signaling and adhesion pathways</title><p hwp:id="p-88">To identify how <italic toggle="yes">MaTAR20</italic> impacts Vegf signaling, we further investigated the molecular mechanism by which the lncRNA acts. First, we performed differential RNA- seq, comparing <italic toggle="yes">MaTAR20</italic> KO to control cells. A total of 223 genes were differentially expressed (p &lt; 0.05), with 129 genes down- and 94 genes up-regulated in the KO cells (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Figure 7A</xref>, Supplementary Figure S7B, Supplementary Table S2). Interestingly, one of the most up-regulated genes was <italic toggle="yes">Vascular endothelial growth inhibitor</italic> (<italic toggle="yes">Vegi</italic>), also known as <italic toggle="yes">Tumor necrosis factor (TNF)-like cytokine 1A (TL1A)/TNF superfamily member 15</italic> (<italic toggle="yes">Tnfsf15</italic>). In agreement with our co-expression analysis (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-5" hwp:rel-id="F6">Figure 6A</xref>), we observed an overall dysregulation of the VEGF signaling pathway and of hypoxia-inducible factor 1 (HIF-1) signaling, another pathway essential for angiogenesis (<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>) (Supplementary Table S3). In addition, pathways involved in cancer signaling such as the MAPK, PI3K-Akt and</p><fig id="fig7" position="float" orientation="portrait" fig-type="figure" hwp:id="F7" hwp:rev-id="xref-fig-7-1 xref-fig-7-2 xref-fig-7-3 xref-fig-7-4 xref-fig-7-5 xref-fig-7-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG7</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">fig7</object-id><label>Figure 7:</label><caption hwp:id="caption-7"><title hwp:id="title-40">RNA-seq and ChIRP-seq identify <italic toggle="yes">Tnfsf15</italic> as a direct <italic toggle="yes">MaTAR20</italic> target gene</title><p hwp:id="p-89"><bold>A:</bold> RNA-seq. Heatmap of significantly differentially expressed genes comparing <italic toggle="yes">MaTAR20</italic> KO and Ren cells. N1-3 indicate three independent biological replicates.</p><p hwp:id="p-90"><bold>B:</bold> ChIRP-seq. qRT-PCR to determine the efficiency of the ChIRP assay. Both <italic toggle="yes">MaTAR20</italic> probe pools enrich <italic toggle="yes">MaTAR20</italic>, with Pool 2 being more efficient. “Cyclo B” indicates a separate pull-down experiment with oligonucleotides specific for the <italic toggle="yes">cyclophilin B</italic> mRNA, which was used as a specificity control. Percentage of MaTAR20 or CycloB pull-down in relation to input is shown. Bars denote the average of at least 3 replicates +/- SD.</p><p hwp:id="p-91"><bold>C:</bold> ChIRP-seq. Venn diagram illustrating the overlap of ChIRP-seq performed with Pool1 vs Pool2 probes. Genes also identified in the negative control (Cyclo B) pull-down were removed from the target lists. 183 genes overlap between both ChIRP probe pools, with Pool1 enriching more genes than Pool 2 overall. All ChIRP experiments were performed in three independent replicates.</p><p hwp:id="p-92"><bold>D:</bold> Venn diagram illustrating the overlap of the 182 target genes identified by ChIRP-seq and the 223 differentially expressed genes according to RNA-seq. 2 genes are both direct genomic binding partners of <italic toggle="yes">MaTAR20</italic> and are differentially expressed upon <italic toggle="yes">MaTAR20</italic> loss.</p><p hwp:id="p-93"><bold>E:</bold> RNA-seq. Expression of Tnfsf15 and Rab27b, comparing the mean log2 fold-change in the two <italic toggle="yes">MaTAR20</italic> KO cell lines (“MaTAR20 KO”) to the mean log2 fold-change of the Ren negative control cell lines (“Control”).</p><p hwp:id="p-94"><bold>F</bold>: qRT-PCR to validate direct <italic toggle="yes">MaTAR20</italic> binding to the <italic toggle="yes">Tnfsf15</italic> locus. Four tiling primer pairs were designed to two putative <italic toggle="yes">MaTAR20</italic> binding regions in proximity to the <italic toggle="yes">Tnfsf15</italic> gene. A negative control region, located between p1/p2 and p3/p4, shows no <italic toggle="yes">MaTAR20</italic> enrichment. CycloB probes control for unspecific binding at all tested sites. Bars denote the mean of at least two biological replicates +/- SD.</p></caption><graphic xlink:href="437774v3_fig7" position="float" orientation="portrait" hwp:id="graphic-7"/></fig><p hwp:id="p-95">TNF axes were altered, as were several cell adhesion pathways, including “Focal adhesion” and “Tight junctions” (Supplementary Table S3). Several of these pathways were previously identified in our co-expression analysis as well (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-6" hwp:rel-id="F6">Figure 6A</xref>). Differential expression of important cell signaling genes likely contributes to the altered phenotypes we observed upon <italic toggle="yes">MaTAR20</italic> loss, such as reduced organoid branching and tumor cell growth. Changes in cell adhesion pathways may explain the enhanced adhesion phenotype observed in <italic toggle="yes">MaTAR20</italic> KO cells (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-9" hwp:rel-id="F2">Figure 2E</xref>), along with reduced migration and metastatic burden upon KD of the lncRNA.</p></sec><sec id="s3j" hwp:id="sec-30"><title hwp:id="title-41"><italic toggle="yes">MaTAR20</italic> regulates gene expression by direct binding to <italic toggle="yes">Tnfsf15</italic></title><p hwp:id="p-96">RNA-seq identifies all differentially expressed genes upon <italic toggle="yes">MaTAR20</italic> loss, both effects due to direct binding and regulation of the gene by <italic toggle="yes">MaTAR20</italic>, as well as any secondary or tertiary downstream effects. To hone in on direct targets of <italic toggle="yes">MaTAR20</italic>, we performed Chromatin Isolation by RNA Purification (ChIRP, (<xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>)) using two separate pools of nine tiling oligonucleotides each. Both pools were able to enrich <italic toggle="yes">MaTAR20</italic>, with pool 2 showing overall better pull-down performance (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-2" hwp:rel-id="F7">Figure 7B</xref>). The difference in enrichment could be due to one or several oligonucleotides in pool 1 being obstructed from binding to <italic toggle="yes">MaTAR20</italic>, caused by secondary structures or competition with putative protein interaction partners. A negative control pull-down reaction for the mRNA <italic toggle="yes">cyclophilin B</italic> (<italic toggle="yes">CycloB</italic>) was performed as well to control for unspecific binding of nucleic acids to biotinylated oligonucleotides and/or streptavidin beads (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-3" hwp:rel-id="F7">Figure 7B</xref>).</p><p hwp:id="p-97">We performed three independent replicates of ChIRP-seq with both probe pools and <italic toggle="yes">CycloB</italic> negative control probes, and compared genes bound to <italic toggle="yes">MaTAR20</italic> in both pools. The highest genomic peak score in both pools was as expected to the <italic toggle="yes">MaTAR20</italic> locus itself, a similar observation was made in regard to <italic toggle="yes">MaTAR25</italic> lncRNA (<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-6" hwp:rel-id="ref-13">13</xref>). Both pool 1 and pool 2 were enriched for genes involved in cancer signaling and adhesion pathways that were also identified in our RNA-seq analysis, such as PI3K-Akt and MAPK signaling, “Focal adhesion” and “ECM-receptor interactions” (Supplementary Table S4). The more efficient pool 2 pull-down was also enriched for VEGF and HIF-1 signaling pathways (Supplementary Table S4). On an individual gene level, we assigned the identified peaks to the nearest gene and were able to identify 574 genes bound by <italic toggle="yes">MaTAR20</italic> in pool1 and 2,514 genes in pool 2 (excluding <italic toggle="yes">MaTAR20</italic> itself, as well as all genes that were also found to bind to the negative control <italic toggle="yes">CycloB</italic> probe set) (Supplementary Table S5), with an overlap of 182 target genes bound by <italic toggle="yes">MaTAR20</italic> in both probe pools (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-4" hwp:rel-id="F7">Figure 7C</xref>, Supplementary Table S5).</p><p hwp:id="p-98">Comparing RNA-seq and ChIRP-seq results, two genes were identified to be direct binding partners of <italic toggle="yes">MaTAR20</italic> and also differentially expressed in <italic toggle="yes">MaTAR20</italic> KO cells (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-5" hwp:rel-id="F7">Figure 7D</xref>): <italic toggle="yes">Tnfsf15</italic> and <italic toggle="yes">Rab27b</italic>. While <italic toggle="yes">Tnfsf15</italic> was significantly up-regulated upon <italic toggle="yes">MaTAR20</italic> loss, <italic toggle="yes">Rab27b</italic> was repressed (<xref rid="fig7" ref-type="fig" hwp:id="xref-fig-7-6" hwp:rel-id="F7">Figure 7E</xref>). Up-regulation of <italic toggle="yes">Tnfsf15</italic> was confirmed at the protein level in immunohistochemistry assays on tumor sections from <italic toggle="yes">MaTAR20</italic> ASO treated animals (Supplementary Figure S6F). To further establish a direct relationship between <italic toggle="yes">MaTAR20</italic> and <italic toggle="yes">Tnfsf15</italic> expression levels, we performed rescue assays over-expressing ectopic <italic toggle="yes">MaTAR20</italic> in KO cells and observed decreased expression of <italic toggle="yes">Tnfsf15</italic> as compared to the <italic toggle="yes">MaTAR20</italic> KO cells treated with just the bavkbone plasmid (Supplementary Figure S7C).</p><p hwp:id="p-99">We performed ChIRP-qPCR at the <italic toggle="yes">Tnfsf15</italic> gene locus to validate direct binding of the lncRNA (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-7" hwp:rel-id="F6">Figure 6F</xref>). Our <italic toggle="yes">MaTAR20</italic> ChIRP-seq data identified two putative lncRNA binding regions, one about 5 kb downstream and the second about 15 kb downstream of the <italic toggle="yes">Tnfsf15</italic> gene (Supplementary Figure S7D). We designed two primer pairs for each region (p1 and p2 for -15 kb, p3 and p4 for -5 kb), and a primer pair for a negative control region in between the two putative binding sites, at about -10 kb. Cyclo B probes served as a negative control for all tested regions, representing background noise. Our results indicate that both <italic toggle="yes">MaTAR20</italic> probe pools were able to specifically detect the lncRNA at the -5 kb site, while only the more efficient pool2 could also enrich for MaTAR20 at the - 15 kb region. This may indicate higher levels of MaTAR20 binding to the <italic toggle="yes">Tnfsf15</italic> -5 kb site, which likely represents a <italic toggle="yes">Tnfsf15</italic> enhancer element. Overall, our results confirm that <italic toggle="yes">MaTAR20</italic> can regulate gene expression by directly binding to target genes such as <italic toggle="yes">Tnfsf15</italic>.</p><p hwp:id="p-100">Based on our findings, we conclude that <italic toggle="yes">MaTAR20</italic> reduces or inhibits the expression of <italic toggle="yes">Tnfsf15</italic> by directly binding to its genomic locus. Tnfsf15 is a cytokine that has been described to inhibit VEGF expression (<xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>) and, more generally, VEGF driven angiogenesis (<xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>). Therefore, we hypothesize that loss of <italic toggle="yes">MaTAR20</italic> leads to reduced tumor angiogenesis (<xref rid="fig8" ref-type="fig" hwp:id="xref-fig-8-1" hwp:rel-id="F8">Figure 8</xref>). The proposed molecular mechanism agrees with the observed phenotype: delayed tumor onset, smaller tumors and increased necrosis, combined with lower metastatic burden in the lungs.</p><fig id="fig8" position="float" orientation="portrait" fig-type="figure" hwp:id="F8" hwp:rev-id="xref-fig-8-1 xref-fig-8-2 xref-fig-8-3 xref-fig-8-4 xref-fig-8-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIG8</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F8</object-id><object-id pub-id-type="publisher-id">fig8</object-id><label>Figure 8:</label><caption hwp:id="caption-8"><title hwp:id="title-42"><italic toggle="yes">MaTAR20</italic> knockdown leads to smaller, necrotic tumors and reduced metastasis</title><p hwp:id="p-101"><bold>A:</bold> During cancer progression, tumors secret pro-angiogenic factors to recruit blood vessels. Increased vasculature allows for steady tumor growth while also increasing the chances for metastatic spread.</p><p hwp:id="p-102"><bold>B:</bold> In the absence of <italic toggle="yes">MaTAR20</italic>, tumor growth is slowed down, tumor necrosis increases, and metastasis is reduced. We hypothesize that this could be due to the observed down-regulation of <italic toggle="yes">Vegf-B</italic>, which may in part be caused by direct binding of <italic toggle="yes">MaTAR20</italic> to <italic toggle="yes">Tnfsf15</italic>. Additional players such as protein binding partners may be of importance and will be elucidated further in future studies.</p></caption><graphic xlink:href="437774v3_fig8" position="float" orientation="portrait" hwp:id="graphic-8"/></fig></sec></sec><sec id="s4" hwp:id="sec-31"><title hwp:id="title-43">Discussion</title><p hwp:id="p-103">Here, we investigated <italic toggle="yes">MaTAR20</italic>, a lncRNA expressed at high levels in mammary tumors. Loss of <italic toggle="yes">MaTAR20</italic> by either ASO-mediated knockdown or CRISPR/Cas9 genome editing in mammary tumor cells leads to reduced proliferation, invasion and organoid branching <italic toggle="yes">in vitro</italic>. In mouse models of BC, treatment with ASOs targeting <italic toggle="yes">MaTAR20</italic> causes delayed tumor onset, reduced tumor growth and overall reduced metastatic burden to the lungs. We were able to confirm the observed phenotype using different ASO sequences, different ASO chemistries (MOE and cET), and in different mouse background strains (FVB and C57/Bl6). Furthermore, our studies of human <italic toggle="yes">MaTAR20</italic> in two loss-of-function and one gain-of-function models further corroborate that this lncRNA is a driver of BC cell growth and migration and may represent a promising new therapeutic target. We propose that ASOs targeting <italic toggle="yes">MaTAR20</italic> could be a viable new adjunct therapy, as we obtained highly efficient lncRNA knockdown in tumors upon subcutaneous delivery. We did not observe any adverse reactions in other mouse tissues or the animal overall, potentially because <italic toggle="yes">MaTAR20</italic> is expressed at highest levels in the tumor, restricting the effect of <italic toggle="yes">MaTAR20</italic> KD mostly to tumor tissue. Additional detailed studies of the human orthologue <italic toggle="yes">hMaTAR20</italic> (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-12" hwp:rel-id="ref-7">7</xref>) will be essential to investigate the potential of the lncRNA as a new therapeutic target in breast cancer. We observed cystic, differentiated metastases in <italic toggle="yes">MaTAR20</italic> ASO-mediated mice, suggesting the treatment may have potential to impact already existing metastases in the lungs. Future investigation of the impact of <italic toggle="yes">MaTAR20</italic> on already existing metastatic nodules will be of particular value, as patients with advanced disease would benefit from a therapeutic approach that is able to attack and/or prevent the formation of metastases.</p><p hwp:id="p-104">Our molecular data indicates that the nuclear-retained lncRNA <italic toggle="yes">MaTAR20</italic> drives tumor growth and metastasis by impacting the expression of important cancer signaling pathways and cell adhesion molecules. These findings are reflected in the observed reduction of cell proliferation, migratory potential and formation of cell protrusions in 2D and 3D cell culture systems. One particular pathway that stood out across all our analyses is VEGF signaling and angiogenesis, seemingly centering on Vegf-B in our system. VEGF-B produced by cancer cells has been described to lead to leaky vascular networks, which in turn enables the tumor to invade its surrounding tissue with high efficiency (<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-1" hwp:rel-id="ref-47">47</xref>). In addition, high VEGF-B levels were associated with poor prognosis (<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-2" hwp:rel-id="ref-47">47</xref>). Inhibition of tumor-specific VEGF-B has been suggested as an interesting approach to inhibit cancer progression and metastasis, with VEGF-B knockdown leading to reduced pulmonary metastasis in a mouse model of melanoma (<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-3" hwp:rel-id="ref-47">47</xref>). As <italic toggle="yes">MaTAR20</italic> also leads to reduced lung metastatic nodules, we hypothesize that it may do so by regulating Vegf-B expression. In addition, non-angiogenic functions of VEGF-B have been described previously in the context of invasive BC, which could also play a role here (<xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref>).</p><p hwp:id="p-105">Our ChIRP assays indicate that <italic toggle="yes">MaTAR20</italic> does not directly bind to the <italic toggle="yes">Vegf-B</italic> gene, but to a number of other angiogenesis-related genes such as <italic toggle="yes">angiopoietin 2</italic>, among many others. Of the 182 genes identified by ChIRP-seq analysis, two also show altered expression in <italic toggle="yes">MaTAR20</italic> KO cells: <italic toggle="yes">Tnfsf15</italic> and <italic toggle="yes">Rab27b</italic>. Tnfsf15 is a cytokine usually expressed in established vasculature but down-regulated in cancer lesions to allow for neovascularization (<xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-2" hwp:rel-id="ref-46">46</xref>,<xref ref-type="bibr" rid="c49" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref>,<xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref>). Vegf and Tnfsf15 serve opposing functions, with carefully balanced expression modulation of both factors playing key roles in vascular and immune homeostasis. We suggest that <italic toggle="yes">MaTAR20</italic> regulates the balance of these proteins by directly binding to the <italic toggle="yes">Tnfsf15</italic> locus and repressing the gene during tumor progression (<xref rid="fig8" ref-type="fig" hwp:id="xref-fig-8-2" hwp:rel-id="F8">Figure 8</xref>). Reduced Tnfsf15 levels allow the tumor to recruit blood vessels, which is essential for sustained tumor growth and enables intravasation of cancer cells into the circulation, leading to metastasis (<xref rid="fig8" ref-type="fig" hwp:id="xref-fig-8-3" hwp:rel-id="F8">Figure 8A</xref>). In the absence of <italic toggle="yes">MaTAR20</italic>, we hypothesize that Tnfsf15 expression will be re-activated and neovascularization of the tumor is inhibited, which would agree with our observed reduction in Vegf-A, Vegf-B and CD31+ cells (<xref rid="fig8" ref-type="fig" hwp:id="xref-fig-8-4" hwp:rel-id="F8">Figure 8B</xref>). In BC, high levels of Tnfsf15 in clinical samples were associated with disease-free survival and overall better prognosis (<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-1" hwp:rel-id="ref-51">51</xref>). This further solidifies our hypothesis that tumor-specific up-regulation of Tnfsf15 via ASO-mediated <italic toggle="yes">MaTAR20</italic> knockdown could be a promising therapeutic approach. As the lncRNA is expressed in high levels only in cancer lesions, we suggest that consequences of <italic toggle="yes">MaTAR20</italic> KD, including reduced neovascularization, are restricted to tumor tissue as well, representing an attractive new approach of tumor-specific inhibition of angiogenesis.</p><p hwp:id="p-106">In addition to regulating angiogenesis, Tnfsf15 has also been described to be involved in dendritic cell maturation and T-cell co-activation (<xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-2" hwp:rel-id="ref-50">50</xref>). Future studies are required to conclude if loss of <italic toggle="yes">MaTAR20</italic> also impacts immune cells in a cancer context, or if the observed phenotype is in fact driven by reduced vascularization. Further investigation is also required into the second identified <italic toggle="yes">MaTAR20</italic> target gene, <italic toggle="yes">Rab27b</italic>. The small secretory GTPase has been described to control vesicle exocytosis and to deliver pro-invasive growth regulators into the tumor microenvironment (<xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-1" hwp:rel-id="ref-52">52</xref>), and has recently been associated with VEGF signaling in cancer as well (<xref ref-type="bibr" rid="c53" hwp:id="xref-ref-53-1" hwp:rel-id="ref-53">53</xref>). Rab27b has been reported to promote proliferation and invasiveness of ER+ BC cells <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, and has been associated with lymph node metastasis and differentiation grade in ER+ human tumors (<xref ref-type="bibr" rid="c54" hwp:id="xref-ref-54-1" hwp:rel-id="ref-54">54</xref>). We observed that loss of <italic toggle="yes">MaTAR20</italic> leads to reduced Rab27b expression, which may further contribute to the decrease in proliferative and migratory potential we observed here. Future studies will elucidate the detailed regulatory mechanism of Rab27b by <italic toggle="yes">MaTAR20</italic>.</p></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-44">Acknowledgements</title><p hwp:id="p-107">We thank members of the Spector and Diermeier labs for critical discussions and advice throughout the course of this study. We thank Dr. Mikala Egeblad (CSHL) for providing MMTV-PyMT mice and Dr. Fred R. Miller (Wayne State University) for providing 4T1 cells. We acknowledge the CSHL Cancer Center Shared Resources (Microscopy, Flow Cytometry, Animal, Histology, and Next-Gen Sequencing) for services and technical expertise (NCI 2P3OCA45508). We thank David Jackson (CSHL) and Zachary Lippman (CSHL) for facilitating access to the SEM instruments. MCF10A and T47D cells used in this study were a generous gift of the Dunbier lab (Department of Biochemistry, University of Otago). We would also like to thank Robert Porteous and the Histology facility at the University of Otago and Bronwyn Carlisle (Department of Biochemistry) for her assistance with the <italic toggle="yes">MaTAR20</italic> model illustration (<xref rid="fig8" ref-type="fig" hwp:id="xref-fig-8-5" hwp:rel-id="F8">Figure 8</xref>).</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-45">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1 xref-ref-1-2 xref-ref-1-3"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Siegel RL"><surname>Siegel</surname> <given-names>RL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miller KD"><surname>Miller</surname> <given-names>KD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fuchs HE"><surname>Fuchs</surname> <given-names>HE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jemal A"><surname>Jemal</surname> <given-names>A</given-names></string-name>. <article-title hwp:id="article-title-2">Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians</article-title>. <source hwp:id="source-1">American Cancer Society</source>; <year>2021</year>;<volume>71</volume>:<fpage>7</fpage>–<lpage>33</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Gupta RA"><surname>Gupta</surname> <given-names>RA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shah N"><surname>Shah</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang KC"><surname>Wang</surname> <given-names>KC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim J"><surname>Kim</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Horlings HM"><surname>Horlings</surname> <given-names>HM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wong DJ"><surname>Wong</surname> <given-names>DJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-3">Long non- coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis</article-title>. <source hwp:id="source-2">Nature</source>. <year>2010</year>;<volume>464</volume>:<fpage>1071</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Prensner JR"><surname>Prensner</surname> <given-names>JR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Iyer MK"><surname>Iyer</surname> <given-names>MK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balbin OA"><surname>Balbin</surname> <given-names>OA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dhanasekaran SM"><surname>Dhanasekaran</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cao Q"><surname>Cao</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brenner JC"><surname>Brenner</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-4">Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression</article-title>. <source hwp:id="source-3">Nat Biotechnol</source>. <year>2011</year>;<volume>29</volume>:<fpage>742</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.4" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Tseng Y-Y"><surname>Tseng</surname> <given-names>Y-Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Moriarity BS"><surname>Moriarity</surname> <given-names>BS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gong W"><surname>Gong</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Akiyama R"><surname>Akiyama</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tiwari A"><surname>Tiwari</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kawakami H"><surname>Kawakami</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-5">PVT1 dependence in cancer with MYC copy-number increase</article-title>. <source hwp:id="source-4">Nature</source>. <year>2014</year>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Xing Z"><surname>Xing</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin A"><surname>Lin</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li C"><surname>Li</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liang K"><surname>Liang</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang S"><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu Y"><surname>Liu</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <source hwp:id="source-5">lncRNA directs cooperative epigenetic regulation downstream of chemokine signals</source>. <year>2014</year>;<volume>159</volume>:<fpage>1110</fpage>–<lpage>25</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1 xref-ref-6-2"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Arun G"><surname>Arun</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Diermeier S"><surname>Diermeier</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Akerman M"><surname>Akerman</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chang K-C"><surname>Chang</surname> <given-names>K-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wilkinson JE"><surname>Wilkinson</surname> <given-names>JE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hearn S"><surname>Hearn</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-6">Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss</article-title>. <source hwp:id="source-6">Genes &amp; Development</source>. <year>2016</year>;<volume>30</volume>:<fpage>34</fpage>–<lpage>51</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1 xref-ref-7-2 xref-ref-7-3 xref-ref-7-4 xref-ref-7-5 xref-ref-7-6 xref-ref-7-7 xref-ref-7-8 xref-ref-7-9 xref-ref-7-10 xref-ref-7-11 xref-ref-7-12"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Diermeier SD"><surname>Diermeier</surname> <given-names>SD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chang K-C"><surname>Chang</surname> <given-names>K-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Freier SM"><surname>Freier</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Song J"><surname>Song</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Demerdash El O"><surname>Demerdash El</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Krasnitz A"><surname>Krasnitz</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-7">Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration</article-title>. <source hwp:id="source-7">Cell Reports</source>. <year>2016</year>;<volume>17</volume>:<fpage>261</fpage>–<lpage>74</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Chakravarty D"><surname>Chakravarty</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sboner A"><surname>Sboner</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nair SS"><surname>Nair</surname> <given-names>SS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Giannopoulou E"><surname>Giannopoulou</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li R"><surname>Li</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hennig S"><surname>Hennig</surname> <given-names>S</given-names></string-name>, et al. <article-title hwp:id="article-title-8">The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer</article-title>. <source hwp:id="source-8">Nature Communications. Nature Publishing Group</source>; <year>2014</year>;<volume>5</volume>:<fpage>5383</fpage>–<lpage>16</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Sang L-J"><surname>Sang</surname> <given-names>L-J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ju H-Q"><surname>Ju</surname> <given-names>H-Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu G-P"><surname>Liu</surname> <given-names>G-P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tian T"><surname>Tian</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ma G-L"><surname>Ma</surname> <given-names>G-L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lu Y-X"><surname>Lu</surname> <given-names>Y-X</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling</article-title>. <source hwp:id="source-9">Molecular Cell. Elsevier Inc</source>; <year>2018</year>;<volume>72</volume>:<fpage>71</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.10" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Hu Q"><surname>Hu</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ye Y"><surname>Ye</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chan L-C"><surname>Chan</surname> <given-names>L-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li Y"><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liang K"><surname>Liang</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin A"><surname>Lin</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-10">Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression</article-title>. <source hwp:id="source-10">Nature Immunology. Springer US</source>; <year>2019</year>;:<fpage>1</fpage>–<lpage>24</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.11" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Luo H"><surname>Luo</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhu G"><surname>Zhu</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xu J"><surname>Xu</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lai Q"><surname>Lai</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yan B"><surname>Yan</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guo Y"><surname>Guo</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-11">HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice</article-title>. <source hwp:id="source-11">Cancer Cell. Elsevier Inc</source>; <year>2019</year>;:<fpage>1</fpage>–<lpage>24</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Silva-Fisher JM"><surname>Silva-Fisher</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dang HX"><surname>Dang</surname> <given-names>HX</given-names></string-name>, <string-name name-style="western" hwp:sortable="White NM"><surname>White</surname> <given-names>NM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Strand MS"><surname>Strand</surname> <given-names>MS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Krasnick BA"><surname>Krasnick</surname> <given-names>BA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rozycki EB"><surname>Rozycki</surname> <given-names>EB</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-12">Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression</article-title>. <source hwp:id="source-12">Nature Communications</source>. <year>2020</year>;<volume>11</volume>:<fpage>2156</fpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2 xref-ref-13-3 xref-ref-13-4 xref-ref-13-5 xref-ref-13-6"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.13" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Chang K-C"><surname>Chang</surname> <given-names>K-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Diermeier SD"><surname>Diermeier</surname> <given-names>SD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yu AT"><surname>Yu</surname> <given-names>AT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brine LD"><surname>Brine</surname> <given-names>LD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Russo S"><surname>Russo</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bhatia S"><surname>Bhatia</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-13">MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression</article-title>. <source hwp:id="source-13">Nature Communications. Springer US</source>; <year>2020</year>;:<fpage>1</fpage>–<lpage>19</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Yan X"><surname>Yan</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hu Z"><surname>Hu</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Feng Y"><surname>Feng</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hu X"><surname>Hu</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yuan J"><surname>Yuan</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhao SD"><surname>Zhao</surname> <given-names>SD</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-14">Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers</article-title>. <source hwp:id="source-14">Cancer Cell. Elsevier Inc</source>; <year>2015</year>;<volume>28</volume>:<fpage>529</fpage>–<lpage>40</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Ransohoff JD"><surname>Ransohoff</surname> <given-names>JD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wei Y"><surname>Wei</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Khavari PA"><surname>Khavari</surname> <given-names>PA</given-names></string-name>. <article-title hwp:id="article-title-15">The functions and unique features of long intergenic non-coding RNA</article-title>. <source hwp:id="source-15">Nature Reviews Molecular Cell Biology. Nature Publishing Group</source>; <year>2018</year>;<volume>19</volume>:<fpage>143</fpage>–<lpage>57</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Huarte M"><surname>Huarte</surname> <given-names>M</given-names></string-name>. <article-title hwp:id="article-title-16">The emerging role of lncRNAs in cancer</article-title>. <source hwp:id="source-16">Nature Medicine</source>. <year>2015</year>;<volume>21</volume>:<fpage>1253</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1 xref-ref-17-2"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Arun G"><surname>Arun</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Diermeier SD"><surname>Diermeier</surname> <given-names>SD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spector DL"><surname>Spector</surname> <given-names>DL</given-names></string-name>. <article-title hwp:id="article-title-17">Therapeutic Targeting of Long Non-Coding RNAs in Cancer</article-title>. <source hwp:id="source-17">Trends Mol Med</source>. <year>2018</year>;<volume>24</volume>:<fpage>257</fpage>–<lpage>77</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Gutschner T"><surname>Gutschner</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hammerle M"><surname>Hammerle</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Eissmann M"><surname>Eissmann</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hsu J"><surname>Hsu</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim Y"><surname>Kim</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hung G"><surname>Hung</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-18">The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells</article-title>. <source hwp:id="source-18">Cancer Research</source>. <year>2013</year>;<volume>73</volume>:<fpage>1180</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Ewald AJ"><surname>Ewald</surname> <given-names>AJ</given-names></string-name>. <article-title hwp:id="article-title-19">Isolation of mouse mammary organoids for long-term time-lapse imaging</article-title>. <source hwp:id="source-19">Cold Spring Harb Protoc</source>. <year>2013</year>;<volume>2013</volume>:<fpage>130</fpage>–<lpage>3</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.20" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Park J"><surname>Park</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wysocki RW"><surname>Wysocki</surname> <given-names>RW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Amoozgar Z"><surname>Amoozgar</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maiorino L"><surname>Maiorino</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fein MR"><surname>Fein</surname> <given-names>MR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jorns J"><surname>Jorns</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-20">Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps</article-title>. <source hwp:id="source-20">Sci Transl Med</source>. <year>2016</year>;<volume>8</volume>:361ra138.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1 xref-ref-21-2 xref-ref-21-3"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Nowak DG"><surname>Nowak</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Katsenelson KC"><surname>Katsenelson</surname> <given-names>KC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Watrud KE"><surname>Watrud</surname> <given-names>KE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chen M"><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mathew G"><surname>Mathew</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="D’Andrea VD"><surname>D’Andrea</surname> <given-names>VD</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-21">The PHLPP2 phosphatase is a druggable driver of prostate cancer progression</article-title>. <source hwp:id="source-21">The Journal of Cell Biology</source>. <year>2019</year>;<volume>218</volume>:<fpage>1943</fpage>–<lpage>57</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1 xref-ref-22-2"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Minn AJ"><surname>Minn</surname> <given-names>AJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gupta GP"><surname>Gupta</surname> <given-names>GP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Siegel PM"><surname>Siegel</surname> <given-names>PM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bos PD"><surname>Bos</surname> <given-names>PD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shu W"><surname>Shu</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Giri DD"><surname>Giri</surname> <given-names>DD</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-22">Genes that mediate breast cancer metastasis to lung</article-title>. <source hwp:id="source-22">Nat Cell Biol</source>. <year>2005</year>;<volume>436</volume>:<fpage>518</fpage>–<lpage>24</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Tanenbaum ME"><surname>Tanenbaum</surname> <given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gilbert LA"><surname>Gilbert</surname> <given-names>LA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qi LS"><surname>Qi</surname> <given-names>LS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weissman JS"><surname>Weissman</surname> <given-names>JS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vale RD"><surname>Vale</surname> <given-names>RD</given-names></string-name>. <article-title hwp:id="article-title-23">A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging</article-title>. <source hwp:id="source-23">Cell. Elsevier Inc</source>; <year>2014</year>;<volume>159</volume>:<fpage>635</fpage>–<lpage>46</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Liang C-C"><surname>Liang</surname> <given-names>C-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Park AY"><surname>Park</surname> <given-names>AY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guan J-L"><surname>Guan</surname> <given-names>J-L</given-names></string-name>. <article-title hwp:id="article-title-24">In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro</article-title>. <source hwp:id="source-24">Nat Protoc</source>. <year>2007</year>;<volume>2</volume>:<fpage>329</fpage>– <lpage>33</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1 xref-ref-25-2"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Guy CT"><surname>Guy</surname> <given-names>CT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cardiff RD"><surname>Cardiff</surname> <given-names>RD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Muller WJ"><surname>Muller</surname> <given-names>WJ</given-names></string-name>. <article-title hwp:id="article-title-25">Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease</article-title>. <source hwp:id="source-25">Molecular and Cellular Biology</source>. <year>1992</year>;<volume>12</volume>:<fpage>954</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.26" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Bankhead P"><surname>Bankhead</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Loughrey MB"><surname>Loughrey</surname> <given-names>MB</given-names></string-name>, <string-name name-style="western" hwp:sortable="ndez JXAFX"><surname>ndez</surname> <given-names>JXAFX</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dombrowski Y"><surname>Dombrowski</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="McArt DG"><surname>McArt</surname> <given-names>DG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dunne PD"><surname>Dunne</surname> <given-names>PD</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-26">QuPath: Open source software for digital pathology image analysis</article-title>. <source hwp:id="source-26">Sci Rep. Springer US</source>; <year>2017</year>;:<fpage>1</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Dobin A"><surname>Dobin</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Davis CA"><surname>Davis</surname> <given-names>CA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schlesinger F"><surname>Schlesinger</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Drenkow J"><surname>Drenkow</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zaleski C"><surname>Zaleski</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jha S"><surname>Jha</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-27">STAR: ultrafast universal RNA-seq aligner</article-title>. <source hwp:id="source-27">Bioinformatics</source>. <year>2012</year>;<volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Anders S"><surname>Anders</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pyl PT"><surname>Pyl</surname> <given-names>PT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huber W"><surname>Huber</surname> <given-names>W</given-names></string-name>. <article-title hwp:id="article-title-28">HTSeq--a Python framework to work with high- throughput sequencing data</article-title>. <source hwp:id="source-28">Bioinformatics</source>. <year>2015</year>;<volume>31</volume>:<fpage>166</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.29" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Love MI"><surname>Love</surname> <given-names>MI</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huber W"><surname>Huber</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anders S"><surname>Anders</surname> <given-names>S</given-names></string-name>. <article-title hwp:id="article-title-29">Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source hwp:id="source-29">Genome Biol</source>. <year>2014</year>;<volume>15</volume>:<issue>550</issue>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.30" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Luo W"><surname>Luo</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Friedman MS"><surname>Friedman</surname> <given-names>MS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shedden K"><surname>Shedden</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hankenson KD"><surname>Hankenson</surname> <given-names>KD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Woolf PJ"><surname>Woolf</surname> <given-names>PJ</given-names></string-name>. <article-title hwp:id="article-title-30">GAGE: generally applicable gene set enrichment for pathway analysis</article-title>. <source hwp:id="source-30">BMC Bioinformatics</source>. <year>2009</year>;<volume>10</volume>:<issue>161</issue>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Luo W"><surname>Luo</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brouwer C"><surname>Brouwer</surname> <given-names>C</given-names></string-name>. <article-title hwp:id="article-title-31">Pathview: an R/Bioconductor package for pathway-based data integration and visualization</article-title>. <source hwp:id="source-31">Bioinformatics</source>. <year>2013</year>;<volume>29</volume>:<fpage>1830</fpage>–<lpage>1</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Langmead B"><surname>Langmead</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Salzberg SL"><surname>Salzberg</surname> <given-names>SL</given-names></string-name>. <article-title hwp:id="article-title-32">Fast gapped-read alignment with Bowtie 2</article-title>. <source hwp:id="source-32">Nature Methods</source>. <year>2012</year>;<volume>9</volume>:<fpage>357</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Heinz S"><surname>Heinz</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Benner C"><surname>Benner</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spann N"><surname>Spann</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bertolino E"><surname>Bertolino</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin YC"><surname>Lin</surname> <given-names>YC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Laslo P"><surname>Laslo</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-33">Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities</article-title>. <source hwp:id="source-33">Molecular Cell. Elsevier Inc</source>; <year>2010</year>;<volume>38</volume>:<fpage>576</fpage>–<lpage>89</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.34" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Diermeier SD"><surname>Diermeier</surname> <given-names>SD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spector DL"><surname>Spector</surname> <given-names>DL</given-names></string-name>. <article-title hwp:id="article-title-34">Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids</article-title>. <source hwp:id="source-34">BIO-PROTOCOL</source>. <year>2017</year>;<volume>7</volume>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Tuveson D"><surname>Tuveson</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Clevers H"><surname>Clevers</surname> <given-names>H</given-names></string-name>. <article-title hwp:id="article-title-35">Cancer modeling meets human organoid technology</article-title>. <source hwp:id="source-35">Science. American Association for the Advancement of Science</source>; <year>2019</year>;<volume>364</volume>:<fpage>952</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Shamir ER"><surname>Shamir</surname> <given-names>ER</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ewald AJ"><surname>Ewald</surname> <given-names>AJ</given-names></string-name>. <article-title hwp:id="article-title-36">Three-dimensional organotypic culture: experimental models of mammalian biology and disease</article-title>. <source hwp:id="source-36">Nature Reviews Molecular Cell Biology. Nature Publishing Group</source>; <year>2014</year>;<volume>15</volume>:<fpage>647</fpage>–<lpage>64</lpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Aslakson CJ"><surname>Aslakson</surname> <given-names>CJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miller FR"><surname>Miller</surname> <given-names>FR</given-names></string-name>. <article-title hwp:id="article-title-37">Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor</article-title>. <source hwp:id="source-37">Cancer Research</source>. <year>1992</year>;<volume>52</volume>:<fpage>1399</fpage>–<lpage>405</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Pallan PS"><surname>Pallan</surname> <given-names>PS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Allerson CR"><surname>Allerson</surname> <given-names>CR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Berdeja A"><surname>Berdeja</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Seth PP"><surname>Seth</surname> <given-names>PP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Swayze EE"><surname>Swayze</surname> <given-names>EE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Prakash TP"><surname>Prakash</surname> <given-names>TP</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-38">Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs. Chem Commun</article-title>. <source hwp:id="source-38">The Royal Society of Chemistry</source>; <year>2012</year>;<volume>48</volume>:<fpage>8195</fpage>–<lpage>10</lpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Shen X"><surname>Shen</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Corey DR"><surname>Corey</surname> <given-names>DR</given-names></string-name>. <article-title hwp:id="article-title-39">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</article-title>. <source hwp:id="source-39">Nucleic Acids Res</source>. <year>2018</year>;<volume>46</volume>:<fpage>1584</fpage>–<lpage>600</lpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Jiang Q"><surname>Jiang</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ma R"><surname>Ma</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang J"><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wu X"><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jin S"><surname>Jin</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Peng J"><surname>Peng</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-40">LncRNA2Function: a comprehensive resource for functional investigation of human lncRNAs based on RNA-seq data</article-title>. <source hwp:id="source-40">BMC Genomics</source>. <year>2015</year>;<volume>16</volume> <issue>Suppl 3</issue>:<fpage>S2</fpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Guttman M"><surname>Guttman</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Amit I"><surname>Amit</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Garber M"><surname>Garber</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="French C"><surname>French</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin MF"><surname>Lin</surname> <given-names>MF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Feldser D"><surname>Feldser</surname> <given-names>D</given-names></string-name>, et al. <article-title hwp:id="article-title-41">Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals</article-title>. <source hwp:id="source-41">Nature [Internet]. Nature Publishing Group</source>; <year>2009</year>;<volume>457</volume>:<fpage>223</fpage>–<lpage>7</lpage>. Available from: <ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.nature.com/doifinder/10.1038/nature07672" ext-link-type="uri" xlink:href="http://www.nature.com/doifinder/10.1038/nature07672" hwp:id="ext-link-4">http://www.nature.com/doifinder/10.1038/nature07672</ext-link></citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Wilhelm SM"><surname>Wilhelm</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Adnane L"><surname>Adnane</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Newell P"><surname>Newell</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Villanueva A"><surname>Villanueva</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Llovet JM"><surname>Llovet</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lynch M"><surname>Lynch</surname> <given-names>M</given-names></string-name>. <article-title hwp:id="article-title-42">Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</article-title>. <source hwp:id="source-42">Mol Cancer Ther</source>. <year>2008</year>;<volume>7</volume>:<fpage>3129</fpage>–<lpage>40</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Semenza GL."><surname>Semenza</surname> <given-names>GL.</given-names></string-name> <article-title hwp:id="article-title-43">Targeting HIF-1 for cancer therapy</article-title>. <source hwp:id="source-43">Nat Rev Cancer. Nature Publishing Group</source>; <year>2003</year>;<volume>3</volume>:<fpage>721</fpage>–<lpage>32</lpage>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Chu C"><surname>Chu</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qu K"><surname>Qu</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhong FL"><surname>Zhong</surname> <given-names>FL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Artandi SE"><surname>Artandi</surname> <given-names>SE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chang HY"><surname>Chang</surname> <given-names>HY</given-names></string-name>. <article-title hwp:id="article-title-44">Genomic Maps of Long Noncoding RNA Occupancy Reveal Principles of RNA-Chromatin Interactions</article-title>. <source hwp:id="source-44">Molecular Cell. Elsevier Inc</source>; <year>2011</year>;<volume>44</volume>:<fpage>667</fpage>–<lpage>78</lpage>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Zhang K"><surname>Zhang</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cai H-X"><surname>Cai</surname> <given-names>H-X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gao S"><surname>Gao</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yang G-L"><surname>Yang</surname> <given-names>G-L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Deng H-T"><surname>Deng</surname> <given-names>H-T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xu G-C"><surname>Xu</surname> <given-names>G-C</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-45">TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals</article-title>. <source hwp:id="source-45">Oncotarget. Impact Journals</source>; <year>2016</year>;<volume>7</volume>:<fpage>69436</fpage>–<lpage>49</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1 xref-ref-46-2"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.46" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Yang G-L"><surname>Yang</surname> <given-names>G-L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li L-Y"><surname>Li</surname> <given-names>L-Y</given-names></string-name>. <article-title hwp:id="article-title-46">Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15</article-title>. <source hwp:id="source-46">Signal Transduction and Targeted Therapy. Springer US</source>; <year>2018</year>;:<fpage>1</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c47" hwp:id="ref-47" hwp:rev-id="xref-ref-47-1 xref-ref-47-2 xref-ref-47-3"><label>47.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Yang X"><surname>Yang</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang Y"><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hosaka K"><surname>Hosaka</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Andersson P"><surname>Andersson</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang J"><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tholander F"><surname>Tholander</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-47">VEGF-B promotes cancer metastasis through a VEGF-A–independent mechanism and serves as a marker of poor prognosis for cancer patients</article-title>. <source hwp:id="source-47">Proceedings of the National Academy of Sciences</source>. <year>2015</year>;<volume>112</volume>:<fpage>E2900</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1"><label>48.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.48" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Gunningham SP"><surname>Gunningham</surname> <given-names>SP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Currie MJ"><surname>Currie</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Han C"><surname>Han</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Robinson BA"><surname>Robinson</surname> <given-names>BA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Scott PA"><surname>Scott</surname> <given-names>PA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harris AL"><surname>Harris</surname> <given-names>AL</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-48">VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol. John Wiley &amp; Sons</article-title>, <source hwp:id="source-48">Ltd</source>; <year>2001</year>;<volume>193</volume>:<fpage>325</fpage>–<lpage>32</lpage>.</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label>49.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.49" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-49"><string-name name-style="western" hwp:sortable="Deng W"><surname>Deng</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gu X"><surname>Gu</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lu Y"><surname>Lu</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gu C"><surname>Gu</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zheng Y"><surname>Zheng</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang Z"><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-49">Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization</article-title>. <source hwp:id="source-49">Angiogenesis. Springer Netherlands</source>; <year>2011</year>;<volume>15</volume>:<fpage>71</fpage>–<lpage>85</lpage>.</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1 xref-ref-50-2"><label>50.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.50" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Zhang Z"><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li L-Y"><surname>Li</surname> <given-names>L-Y</given-names></string-name>. <article-title hwp:id="article-title-50">TNFSF15 Modulates Neovascularization and Inflammation</article-title>. <source hwp:id="source-50">Cancer Microenvironment</source>. <year>2012</year>;<volume>5</volume>:<fpage>237</fpage>–<lpage>47</lpage>.</citation></ref><ref id="c51" hwp:id="ref-51" hwp:rev-id="xref-ref-51-1"><label>51.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.51" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-51"><string-name name-style="western" hwp:sortable="Parr C"><surname>Parr</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gan CH"><surname>Gan</surname> <given-names>CH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Watkins G"><surname>Watkins</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jiang WG"><surname>Jiang</surname> <given-names>WG</given-names></string-name>. <article-title hwp:id="article-title-51">Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients</article-title>. <source hwp:id="source-51">Angiogenesis</source>. <year>2006</year>;<volume>9</volume>:<fpage>73</fpage>–<lpage>81</lpage>.</citation></ref><ref id="c52" hwp:id="ref-52" hwp:rev-id="xref-ref-52-1"><label>52.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.52" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-52"><string-name name-style="western" hwp:sortable="Hendrix A"><surname>Hendrix</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maynard D"><surname>Maynard</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pauwels P"><surname>Pauwels</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Braems G"><surname>Braems</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Denys H"><surname>Denys</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Van den Broecke R"><surname>Van den Broecke</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-52">Effect of the Secretory Small GTPase Rab27B on Breast Cancer Growth, Invasion, and Metastasis</article-title>. <source hwp:id="source-52">J Natl Cancer Inst</source>. <year>2010</year>;<volume>102</volume>:<fpage>866</fpage>–<lpage>80</lpage>.</citation></ref><ref id="c53" hwp:id="ref-53" hwp:rev-id="xref-ref-53-1"><label>53.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.53" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-53"><string-name name-style="western" hwp:sortable="Tsuruda M"><surname>Tsuruda</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yoshino H"><surname>Yoshino</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Okamura S"><surname>Okamura</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kuroshima K"><surname>Kuroshima</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Osako Y"><surname>Osako</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sakaguchi T"><surname>Sakaguchi</surname> <given-names>T</given-names></string-name>, et al. <article-title hwp:id="article-title-53">Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant</article-title>. <string-name name-style="western" hwp:sortable="Dahiya R"><surname>Dahiya</surname> <given-names>R</given-names></string-name>, editor. <source hwp:id="source-53">PLoS ONE</source>. <year>2020</year>;<volume>15</volume>:<fpage>e0232545</fpage>–<lpage>20</lpage>.</citation></ref><ref id="c54" hwp:id="ref-54" hwp:rev-id="xref-ref-54-1"><label>54.</label><citation publication-type="journal" citation-type="journal" ref:id="2021.03.30.437774v3.54" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-54"><string-name name-style="western" hwp:sortable="Li Z"><surname>Li</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fang R"><surname>Fang</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fang J"><surname>Fang</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="He S"><surname>He</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu T"><surname>Liu</surname> <given-names>T</given-names></string-name>. <article-title hwp:id="article-title-54">Functional implications of Rab27 GTPases in Cancer</article-title>. <source hwp:id="source-54">Cell Communication and Signaling</source>; <year>2018</year>;:<fpage>1</fpage>–<lpage>8</lpage>.</citation></ref></ref-list><sec sec-type="display-objects" hwp:id="sec-32"><fig id="figs1" position="float" orientation="portrait" fig-type="figure" hwp:id="F9"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F9</object-id><object-id pub-id-type="publisher-id">figs1</object-id><label>Figure S1:</label><caption hwp:id="caption-9"><p hwp:id="p-108"><bold>A:</bold> qRT-PCR to determine relative <italic toggle="yes">MaTAR20</italic> expression in MMTV-PyMT tumors of different size. “Small” tumors: &lt;200 mm<sup>3</sup>, n=7; “medium” tumors: 300 - 1000 mm<sup>3</sup>, n=4; “large” tumors: &gt;1500 mm<sup>3</sup>, n=3.</p></caption><graphic xlink:href="437774v3_figs1" position="float" orientation="portrait" hwp:id="graphic-9"/></fig><fig id="figs2" position="float" orientation="portrait" fig-type="figure" hwp:id="F10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F10</object-id><object-id pub-id-type="publisher-id">figs2</object-id><label>Figure S2:</label><caption hwp:id="caption-10"><p hwp:id="p-109"><bold>A:</bold> qRT-PCR to determine the relative <italic toggle="yes">MaTAR20</italic> expression in mouse mammary tumor cell lines. Bars denote the mean of three biological replicates +/- SD. <bold>B:</bold> qRT-PCR to determine the relative expression of individual MaTAR20 isoforms in <italic toggle="yes">MaTAR20</italic> promoter deletion cell lines. KO = promoter deletion of 748 bp (combination of gRNAs “+12” and “-736”), Ren = negative control, integration of Cas9 and a gRNA targeting <italic toggle="yes">Renilla</italic> luciferase. Bars denote the mean of two biological replicates +/- SD. <bold>C:</bold> Correlation of <italic toggle="yes">MaTAR20</italic> expression (all isoforms, based on six biological replicates, <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-10" hwp:rel-id="F2">Figure 2B</xref>) and Cas9 expression, as determined by qRT-PCR in three biological replicates.</p></caption><graphic xlink:href="437774v3_figs2" position="float" orientation="portrait" hwp:id="graphic-10"/></fig><fig id="figs3" position="float" orientation="portrait" fig-type="figure" hwp:id="F11"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F11</object-id><object-id pub-id-type="publisher-id">figs3</object-id><label>Figure S3:</label><caption hwp:id="caption-11"><p hwp:id="p-110"><bold>A:</bold> Cell proliferation assay. Number of cells determined after 48 h. Statistical significance was determined comparing KO cells transfected with a <italic toggle="yes">MaTAR20</italic> Tx1 (KO+MaTAR20) to KO cells transfected with an empty backbone (KO+bb) and untransfected KO cells. Control Ren cells are shown for reference. Error bars denote SD, and a two-tailed Student’s t-test was performed comparing KO+bb to KO+<italic toggle="yes">MaTAR20</italic>; * p &lt; 0.05.</p><p hwp:id="p-111"><bold>B:</bold> Cell proliferation assay comparing <italic toggle="yes">MaTAR20</italic> isoform 1 and isoform 2 after 24 and 48 h. Cell counts normalized to KO cells transfected with empty vector (bb). Bars denote the mean of at least two biological replicates +/- SD. Statistical significance was determined with a two-tailed Student’s t-test comparing KO+bb to KO+<italic toggle="yes">MaTAR20</italic>; * p &lt; 0.05, ** p &lt; 0.01</p></caption><graphic xlink:href="437774v3_figs3" position="float" orientation="portrait" hwp:id="graphic-11"/></fig><fig id="figs4" position="float" orientation="portrait" fig-type="figure" hwp:id="F12"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F12</object-id><object-id pub-id-type="publisher-id">figs4</object-id><label>Figure S4:</label><caption hwp:id="caption-12"><p hwp:id="p-112"><bold>A:</bold> RNA-FISH of <italic toggle="yes">hMaTAR20</italic> on a tissue microarray (TMA), comparing expression in breast cancer of different grades to corresponding normal breast tissue. Statistical significance was determined with a one-way ANOVA; *** p &lt; 0.001.</p><p hwp:id="p-113"><bold>B:</bold> qRT-PCR to determine relative <italic toggle="yes">hMaTAR20</italic> expression in a panel of breast cancer cells. Bars denote the mean of three biological replicates +/- SEM. Statistical significance was determined with a one-way ANOVA ;**** p &lt; 0.0001.</p><p hwp:id="p-114"><bold>C:</bold> RNA-FISH of <italic toggle="yes">hMaTAR20</italic> in MDA-MB-231-LM2 (LM2).</p><p hwp:id="p-115"><bold>D:</bold> qRT-PCR to determine relative <italic toggle="yes">hMaTAR20</italic> expression in MDA-MB-231-LM2 (LM2) cells. Ren: control cell line with non-targeting sgRNA. -277; -390: CRISPRi <italic toggle="yes">hMaTAR20</italic> knockdown cell lines, numbers denote distance to the TSS. Bars denote the mean of at least three biological replicates +/- SEM. Statistical significance was determined with a two-tailed Student’s t-test; * p &lt; 0.05.</p><p hwp:id="p-116"><bold>E:</bold> Quantification of LM2 scratch assay. Bars denote the mean of at least three biological replicates +/- SEM. Statistical significance was determined with a two-tailed Student’s t- test; * p &lt; 0.05.</p><p hwp:id="p-117"><bold>F:</bold> Cell proliferation assay comparing growth curves of the Ren negative control to the two <italic toggle="yes">hMaTAR20</italic> KD cell lines. Data points denote the mean of at least three biological replicates +/- SEM.</p><p hwp:id="p-118"><bold>G:</bold> Quantification of LM2 spheroid branching. For each biological replicate, n = 100 spheroids were analyzed (n = 300, total). Bars denote the mean of at least three biological replicates +/- SEM. Statistical significance was determined with a two-tailed Student’s t- test; * p &lt; 0.05.</p></caption><graphic xlink:href="437774v3_figs4" position="float" orientation="portrait" hwp:id="graphic-12"/></fig><fig id="figs5" position="float" orientation="portrait" fig-type="figure" hwp:id="F13"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F13</object-id><object-id pub-id-type="publisher-id">figs5</object-id><label>Figure S5:</label><caption hwp:id="caption-13"><p hwp:id="p-119"><bold>A:</bold> Related to <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-8" hwp:rel-id="F5">Figure 5</xref>, cET experiments: quantification of macro-metastatic nodules, displayed is the average number per lung.</p><p hwp:id="p-120"><bold>B:</bold> Related to <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-9" hwp:rel-id="F5">Figure 5</xref>, cET experiments: Hematoxylin and Eosin staining of fixed lung sections.</p><p hwp:id="p-121"><bold>C:</bold> Related to <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-10" hwp:rel-id="F5">Figure 5</xref>, cET experiments: quantification of metastases by area. Bars represent the mean +/- SEM.</p><p hwp:id="p-122"><bold>D:</bold> MMTV-PyMT (FVB) mice were treated for 6 weeks with MOE ASOs (150 mg/kg/week), either scASO or <italic toggle="yes">MaTAR20</italic> ASO1. Bars / lines denote the mean of biological replicates +/- SEM.</p><p hwp:id="p-123"><bold>E:</bold> Average tumor burden in mm<sup>3</sup> per week in each treatment group, tumor size 100-200 mm<sup>3</sup>, n=5 tumors.</p><p hwp:id="p-124"><bold>F:</bold> Quantification of macro-metastatic nodules, displayed is the average number per lung. Insets show exemplary images of lungs from scASO and ASO1 treated animals.</p><p hwp:id="p-125"><bold>G:</bold> Hematoxylin and Eosin staining of tumor sections. Left: scASO treated tumor. Right: <italic toggle="yes">MaTAR20</italic> ASO1 treated tumor.</p></caption><graphic xlink:href="437774v3_figs5" position="float" orientation="portrait" hwp:id="graphic-13"/></fig><fig id="figs6" position="float" orientation="portrait" fig-type="figure" hwp:id="F14"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F14</object-id><object-id pub-id-type="publisher-id">figs6</object-id><label>Figure S6:</label><caption hwp:id="caption-14"><p hwp:id="p-126">Immunohistochemistry on tumors from animals treated with either scASO or <italic toggle="yes">MaTAR20</italic> ASO. “MOE” = animals in the 2’MOE ASO cohort, “cET” = animals in the cET ASO cohort. Lines within boxplots indicate the median. The y-axis indicates the percentage of each tumor section stained with the respective antibody given a defined detection threshold (0.2 for CD31, 0.5 for all other antibodies). Two technical replicates were measured for each tumor. The axis indicates which ASO chemistry was used (MOE or cET).</p><p hwp:id="p-127"><bold>A:</bold> Ki67 staining</p><p hwp:id="p-128"><bold>B:</bold> Cleaved caspase-3 staining</p><p hwp:id="p-129"><bold>C:</bold> Vegf-A staining</p><p hwp:id="p-130"><bold>D:</bold> Vegf-B staining</p><p hwp:id="p-131"><bold>E:</bold> CD31 staining</p><p hwp:id="p-132"><bold>F:</bold> Tnfsf15 staining</p></caption><graphic xlink:href="437774v3_figs6" position="float" orientation="portrait" hwp:id="graphic-14"/></fig><fig id="figs7" position="float" orientation="portrait" fig-type="figure" hwp:id="F15"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;2021.03.30.437774v3/FIGS7</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F15</object-id><object-id pub-id-type="publisher-id">figs7</object-id><label>Figure S7:</label><caption hwp:id="caption-15"><p hwp:id="p-133"><bold>A:</bold> qRT-PCR to determine the relative <italic toggle="yes">Vegf-B</italic> expression in 4T1 <italic toggle="yes">MaTAR20</italic> KO cells. Cells were transfected either with <italic toggle="yes">MaTAR20</italic> Tx1 (KO+MaTAR20) or an empty backbone (KO+bb). Bars denote the mean of at least three biological replicates +/- SD. Statistical significance was determined with a two-tailed Student’s t-test; * p &lt; 0.05</p><p hwp:id="p-134"><bold>A:</bold> Top 10 up-and down-regulated genes in <italic toggle="yes">MaTAR20</italic> KO cells compared to Ren control cells.</p><p hwp:id="p-135"><bold>B:</bold> Like A, for <italic toggle="yes">Tnfsf15</italic>.</p><p hwp:id="p-136"><bold>C:</bold> UCSC Browser image illustrating <italic toggle="yes">MaTAR20</italic> binding to the <italic toggle="yes">Tnfsf15</italic> locus.</p></caption><graphic xlink:href="437774v3_figs7" position="float" orientation="portrait" hwp:id="graphic-15"/></fig></sec></back></article>
